View source for Bristol Myers Squibb

{{short description|American pharmaceutical company}}
{{About|the pharmaceutical company|the children's hospital in New Jersey|The Bristol-Myers Squibb Children's Hospital}}{{Redirects here|BMY}}
{{Use dmy dates|date=November 2024}}
{{Infobox company
| name = Bristol-Myers Squibb Company
| logo = Bristol-Myers Squibb logo (2020).svg
| image = Bristolmyersprincetonfacility.jpg
| image_size =
| image_caption = A Bristol Myers Squibb research and development facility in [[Lawrence Township, Mercer County, New Jersey|Lawrence, New Jersey]] (corporate headquarters since July 2023)
| trade_name = Bristol Myers Squibb
| former_name = Bristol-Myers Company (1887–1989)
| type = [[Public company|Public]]
| traded_as = {{ubl|{{NYSE|BMY}}|[[S&P 100]] component|[[S&P 500]] component}}
| industry = [[Pharmaceuticals]]
| predecessors = Squibb Corporation (1858–1989)
| founders = {{ubl|[[William McLaren Bristol]]|[[John Ripley Myers]]|[[E. R. Squibb]]}}
| founded = {{Start date and age|1887}}
| hq_location = {{unbulleted list|[[Princeton, New Jersey]], U.S. (registered)|[[Lawrenceville, New Jersey]], U.S. (corporate)}}
| area_served = Worldwide
| key_people = {{unbulleted list|Chris Boerner ([[chairman]] and [[CEO]])|David Elkins ([[CFO]])}}
| revenue = {{increase}} {{US$|48.3 billion|link=yes}} (2024)
| operating_income = {{decrease}} {{US$|-8.4 billion}} (2024)
| net_income = {{decrease}} {{US$|-8.9 billion}} (2024)
| assets = {{decrease}} {{US$|92.6 billion}} (2024)
| equity = {{decrease}} {{US$|16.3 billion}} (2024)
| num_employees = 34,100 (2024)
| website = {{url|https://www.bms.com}}
| footnotes = <ref name=AR>{{cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm |title=Bristol Myers Squibb 2024 Annual Report (Form 10-K) |date=February 12, 2025 |website=SEC.gov |publisher=[[U.S. Securities and Exchange Commission]] |access-date=15 February 2024 }}</ref>
}}

The '''Bristol-Myers Squibb Company''', [[Trade name|doing business as]] '''Bristol Myers Squibb''' ('''BMS'''), is an American multinational [[pharmaceutical company]]. Headquartered in [[Princeton, New Jersey]],<ref name="July 2023 Form 8-K">{{cite web |last1=Bristol-Myers Squibb Company |title=Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 (Form 8-K) |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/14272/000001427223000150/bmy-20230727.htm |website=SEC.gov |date=27 July 2023 |publisher=[[U.S. Securities and Exchange Commission]] |access-date=2 August 2023 |archive-date=2 August 2023 |archive-url=https://web.archive.org/web/20230802135524/https://www.sec.gov/ix?doc=/Archives/edgar/data/14272/000001427223000150/bmy-20230727.htm |url-status=live }}</ref> BMS is one of the world's largest pharmaceutical companies and consistently ranks on the [[Fortune 500|''Fortune'' 500]] list of the largest U.S. corporations. For [[fiscal year|fiscal]] 2022, it had a total revenue of $46.2&nbsp;billion.<ref name=AR />

Bristol Myers Squibb manufactures prescription pharmaceuticals and [[Biopharmaceutical|biologics]] in several therapeutic areas, including [[cancer]], [[HIV/AIDS]], [[cardiovascular disease]], [[diabetes]], [[hepatitis]], [[rheumatoid arthritis]], and [[psychiatric disorders]].

BMS's primary [[research and development]] (R&D) sites are located in [[Lawrence Township, Mercer County, New Jersey|Lawrence, New Jersey]] (formerly Squibb, near Princeton), [[Summit, New Jersey]], formerly HQ of [[Celgene]], [[New Brunswick, New Jersey]]; [[Redwood City, California]]; and [[Seville]] in Spain, with other sites in [[Devens, Massachusetts|Devens]] and [[Cambridge, Massachusetts]]; [[Braine-l'Alleud]], Belgium; [[Tokyo]], Japan; [[Hyderabad]]; [[Bangalore]], India<ref>{{Cite news|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bristol-myers-squibb-to-invest-rs-800-cr-to-set-up-facility-in-hyderabad-for-drug-development-it/articleshow/98170745.cms|title=Bristol Myers Squibb to invest Rs 800 crore to set up facility in Hyderabad for drug development, IT|newspaper=The Economic Times|date=23 February 2023|access-date=5 December 2023|archive-date=5 December 2023|archive-url=https://web.archive.org/web/20231205045859/https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bristol-myers-squibb-to-invest-rs-800-cr-to-set-up-facility-in-hyderabad-for-drug-development-it/articleshow/98170745.cms|url-status=live}}</ref> and [[Metropolitan Borough of Wirral|Wirral]], United Kingdom.<ref>{{cite press release |title=Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park |url=https://www.bms.com/in |access-date=16 May 2012 |url-status=dead |archive-url=https://web.archive.org/web/20120929024338/http://www.bmsi.co.in/bbrc.aspx?section=2|archive-date=29 September 2012}}</ref><ref>{{Cite web|url=https://www.bms.com/about-us/our-company/worldwide-facilities/our-research-facilities.html|title=Worldwide Research and Development Facilities – Bristol Myers Squibb|website=www.bms.com|access-date=7 June 2020|archive-date=7 June 2020|archive-url=https://web.archive.org/web/20200607002847/https://www.bms.com/about-us/our-company/worldwide-facilities/our-research-facilities.html|url-status=live}}</ref> BMS previously had an R&D site in [[Wallingford, Connecticut]] (formerly Bristol-Myers).<ref>{{cite web |title=Bristol-Myers Squibb to lay off 149 as Wallingford, Connecticut, site nears closure |date=17 July 2018 |url=https://www.fiercepharma.com/pharma/bristol-myers-squibb-to-lay-off-149-as-wallingford-site-nears-closure |publisher=Fiercepharma.com |access-date=3 February 2019 |archive-date=4 February 2019 |archive-url=https://web.archive.org/web/20190204014332/https://www.fiercepharma.com/pharma/bristol-myers-squibb-to-lay-off-149-as-wallingford-site-nears-closure |url-status=live }}</ref>

==History==
===Squibb===
{{expand section|date=January 2020}}

[[Image:E.R. Squibb & Son, Northern Blvd., Long Island City. LOC gsc.5a14902.jpg|thumb|left|E.R. Squibb & Son facility in Long Island City, New York, in 1948]]
The Squibb corporation was founded in 1858 by [[Edward Robinson Squibb]] in [[Brooklyn, New York|Brooklyn]], New York.<ref>{{Cite news|last=Gray|first=Christopher|url=https://www.nytimes.com/2012/09/02/realestate/brooklyn-heights-streetscapes-still-in-fashion-a-century-later.html|title=Still in Fashion, a Century Later|date=30 August 2012|work=The New York Times|access-date=20 March 2020|language=en-US|issn=0362-4331|archive-date=20 March 2020|archive-url=https://web.archive.org/web/20200320213513/https://www.nytimes.com/2012/09/02/realestate/brooklyn-heights-streetscapes-still-in-fashion-a-century-later.html|url-status=live}}</ref><ref>{{Cite book|last=Kumar|first=B.|url=https://books.google.com/books?id=0lAjalmgNBUC&q=squibb+corporation+%221858%22&pg=PA54|title=Mega Mergers and Acquisitions: Case Studies from Key Industries|date=14 November 2012|publisher=Springer|isbn=978-1-137-00590-8|language=en|access-date=15 October 2020|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414044838/https://books.google.com/books?id=0lAjalmgNBUC&q=squibb+corporation+%221858%22&pg=PA54|url-status=live}}</ref> Squibb was known as an advocate of quality control and high purity standards early within the pharmaceutical industry.<ref>{{Cite book|url=https://books.google.com/books?id=nNgtGmY7iYIC&q=Squibb+was+known+as+an+advocate+of+quality+control+and+high+purity+standards&pg=PA192|title=The National Druggist|date=1905|language=en|access-date=15 October 2020|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414044936/https://books.google.com/books?id=nNgtGmY7iYIC&q=Squibb+was+known+as+an+advocate+of+quality+control+and+high+purity+standards&pg=PA192|url-status=live}}</ref> He went on to self-publish an alternative to the [[United States Pharmacopeia|U.S. Pharmacopeia]] titled ''Squibb's Ephemeris of Materia Medica,'' after failing to convince the [[American Medical Association]] to incorporate higher purity standards.<ref>{{Cite web|url=https://www.britannica.com/biography/E-R-Squibb|title=E. R. Squibb {{!}} American chemist|website=Encyclopedia Britannica|language=en|access-date=20 March 2020|archive-date=20 March 2020|archive-url=https://web.archive.org/web/20200320213512/https://www.britannica.com/biography/E-R-Squibb|url-status=live}}</ref>

''Materia Medica'', Squibb products, and Edward Squibb's opinion on the fundamentals of pharmacy are found in many medical papers of the late 1800s.<ref>{{cite journal |title=Inverse Type of Temperature in Typhoid Fever, with a Report of Two Cases — Temperature Peculiarities in Epidemics, with a Report of Seven Cases in One Family |journal=Boston Medical and Surgical Journal |date=8 January 1885 |last=Hollopeter |first=W.C. |volume=112 |pages=28–32 |doi=10.1056/NEJM188308301090903 |url=http://www.nejm.org/doi/full/10.1056/NEJM188710271171706 |access-date=25 November 2014 |quote="The writer noticed (in December, 1882) the important fact that when common or Japan camphor and crystallized carbolic acid are mixed together and subjected to heat, a colorless liquid would be the result. The only reference he finds so far with regard to this reaction occurs in the very excellent and valuable scientific publication of Dr. E. R. Squibb, " Ephemeris of Materia Medica", etc., on page 673, vol. ii., No. 5, where a brief allusion appears under the appellation of Compound Alum Powder. Dr. F. R. Squibb, however, in a letter to the writer states that he has " several times before heard of this reaction between phenol and camphor." |archive-date=19 October 2015 |archive-url=https://web.archive.org/web/20151019134348/http://www.nejm.org/doi/full/10.1056/NEJM188710271171706 |url-status=live |url-access=subscription }}</ref><ref>{{cite journal |title=Edward Robinson Squibb (1819–1900): Advocate of Product Standards |journal=Journal of the American Pharmacists Association |year=2003 |last=Worthen |first=Dennis |volume=46 |issue=6 |pages=754–758 |doi=10.1331/1544-3191.46.6.754.Worthen |pmid=17176693 |url=http://japha.org/article.aspx?articleid=1042039|access-date=25 November 2014 |archive-url=https://web.archive.org/web/20140418052223/http://japha.org/article.aspx?articleid=1042039 |archive-date=18 April 2014 |url-status=dead|url-access=subscription }}</ref><ref>{{cite journal|last=Blake|first=J.B.|year=1899|title=Administration of Ether at the Boston City Hospital|url=https://zenodo.org/record/1916260|journal=Boston Med Surg J|volume=141|issue=13|pages=312–314|doi=10.1056/NEJM189909281411303|quote="Until within six months Squibb's other has been exclusively used at the Boston City Hospital. Recently .MeliiHTéift's ether has been tried, ¡uni has given fair satisfaction ; Squibb's is still preferred by most of the house officers."|access-date=5 July 2019|archive-date=27 July 2020|archive-url=https://web.archive.org/web/20200727043210/https://zenodo.org/record/1916260|url-status=live}}<!--|access-date=2014-11-26 --></ref><ref>{{cite journal|last=Brown|first=W.S.|year=1885|title=Forty Year's Experience in Midwifery|url=https://zenodo.org/record/1429884|journal=Boston Medical and Surgical Journal|volume=112|issue=11|page=241|doi=10.1056/nejm188503121121101|quote="One reason why ergot has fallen into disrepute is the poor quality of many specimens offered for sale. Dr. Squibb's aqueous extract rarely disappoints me."|access-date=5 July 2019|archive-date=27 July 2020|archive-url=https://web.archive.org/web/20200727043103/https://zenodo.org/record/1429884|url-status=live}}<!--|access-date=2014-11-25 --></ref> The ''[[American Journal of Pharmaceutical Education|American Journal of Pharmacy]]'' published more than one hundred papers of Squibb's research surrounding the industry.<ref>{{Cite book|last=Capace|first=Nancy|url=https://books.google.com/books?id=u9StYwbI_F8C&q=U.S.+Pharmacopeia+Squibb%27s+Ephemeris+of+Materia+Medica&pg=PA227|title=Encyclopedia of Delaware|date=1 January 2001|publisher=Somerset Publishers, Inc.|isbn=978-0-403-09612-1|language=en|access-date=15 October 2020|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414044849/https://books.google.com/books?id=u9StYwbI_F8C&q=U.S.+Pharmacopeia+Squibb%27s+Ephemeris+of+Materia+Medica&pg=PA227|url-status=live}}</ref>

The sons of Edward Squibb sold the company to Lowell M. Palmer and Theodore Weicker in 1905, who incorporated the company. Around this time, the Squibb logo was developed, which represented the company's products of "uniformity, purity, efficacy, and reliability based on research."<ref>{{Cite web|last=Claire|date=27 August 2013|title=A history of Bristol-Myers Squibb|url=https://pharmaphorum.com/views-and-analysis/a-history-of-bristol-myers-squibb/|access-date=1 August 2021|website=pharmaphorum.com|language=en-GB|archive-date=22 September 2020|archive-url=https://web.archive.org/web/20200922110355/https://pharmaphorum.com/views-and-analysis/a-history-of-bristol-myers-squibb/|url-status=live}}</ref>

Squibb Corporation served as a major supplier of medical goods to the Union Army during the [[American Civil War]], providing portable medical kits containing [[morphine]], surgical anesthetics, and [[quinine]] for the treatment of malaria (which was endemic in most of the Eastern United States at that time).<ref>{{cite book |last=Smith |title= Medicines for the Union Army: the United States Army laboratories during the Civil War|url=https://archive.org/details/medicinesforunio00smit |url-access=registration |publisher= Pharmaceutical Products Press|year= 2001|isbn= 9780789009470}} Accessed 25 November 2014.</ref><ref>{{Cite book|url=https://books.google.com/books?id=ueAJxIW6gu0C&q=Bristol-Myers+Squibb+union+army&pg=RA3-PA24|title=Navy Medicine|date=2005|publisher=Naval Medical Command|language=en|access-date=15 October 2020|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414021917/https://books.google.com/books?id=ueAJxIW6gu0C&q=Bristol-Myers+Squibb+union+army&pg=RA3-PA24|url-status=live}}</ref>

In 1944, Squibb opened the world's largest penicillin plant in [[New Brunswick, New Jersey]].<ref>{{Cite book|last=Rosenbloom|first=Bert|url=https://books.google.com/books?id=6WMJAAAAQBAJ&q=1944&pg=PA609|title=Marketing Channels|date=25 July 2012|publisher=Cengage Learning|isbn=978-1-133-70757-8|language=de|access-date=15 October 2020|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414044926/https://books.google.com/books?id=6WMJAAAAQBAJ&q=1944&pg=PA609|url-status=live}}</ref>
{{clear}}

===Bristol-Myers===
{{expand section|date=January 2020}}
[[File:Sal Hepatica by Bristol Myers Co (1909).jpg|thumb|right|100px|Sal Hepatica (1909)]]
In 1887, [[Hamilton College (New York)|Hamilton College]] graduates [[William McLaren Bristol]] and [[John Ripley Myers]] purchased the Clinton Pharmaceutical company of [[Clinton, Oneida County, New York|Clinton]], New York.<ref name=":7">{{Cite book|last=Cox|first=Jim|url=https://books.google.com/books?id=RwVkMMLqMdkC&q=In+1887%2C+Hamilton+College+graduates+William+McLaren+Bristol+and+John+Ripley+Myers+purchased+the+Clinton+Pharmaceutical+company+of+Clinton%2C+New+York&pg=PA95|title=Sold on Radio: Advertisers in the Golden Age of Broadcasting|date=18 September 2008|publisher=McFarland|isbn=978-0-7864-5176-0|language=en|access-date=15 October 2020|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414022015/https://books.google.com/books?id=RwVkMMLqMdkC&q=In+1887%2C+Hamilton+College+graduates+William+McLaren+Bristol+and+John+Ripley+Myers+purchased+the+Clinton+Pharmaceutical+company+of+Clinton%2C+New+York&pg=PA95|url-status=live}}</ref> In May 1898, they decided to rename it '''Bristol, Myers and Company'''.<ref name=":7" /> Following Myers' death in 1899, Bristol changed the name to the '''Bristol-Myers Corporation'''.<ref name=":7" />

During the 1890s, the company introduced its first nationally recognized product [[Sal Hepatica]], a [[laxative]] mineral salt, followed by [[Ipana]] toothpaste in 1901.<ref name="MarketingChannels">Bert Rosenbloom, ''Marketing Channels'', [https://books.google.com/books?id=6WMJAAAAQBAJ&pg=PA609 Bristol-Myers Squibb] {{Webarchive|url=https://web.archive.org/web/20161224024131/https://books.google.com/books?id=6WMJAAAAQBAJ&pg=PA609 |date=24 December 2016 }}, 2011, page 609</ref><ref>{{Cite web|url=https://www.reporterherald.com/ci_30933687/ipana-toothpaste-tasted-success-early-1900s|title=Ipana toothpaste tasted success in early 1900s|date=20 April 2017|website=Loveland Reporter-Herald|language=en-US|access-date=26 March 2020|archive-date=19 October 2021|archive-url=https://web.archive.org/web/20211019181909/https://www.reporterherald.com/2017/04/20/ipana-toothpaste-tasted-success-in-early-1900s/|url-status=live}}</ref> Other divisions were [[Clairol]] (hair colors and haircare) and [[Drackett]] (household products such as [[Windex]] and [[Drano]]).<ref>{{Cite news|last=Salpukas|first=Agis|url=https://www.nytimes.com/1984/08/16/business/business-people-3-executive-changes-set-by-bristol-myers.html|title=BUSINESS PEOPLE; 3 Executive Changes Set by Bristol-Myers|date=16 August 1984|work=The New York Times|access-date=26 March 2020|language=en-US|issn=0362-4331|archive-date=26 March 2020|archive-url=https://web.archive.org/web/20200326150851/https://www.nytimes.com/1984/08/16/business/business-people-3-executive-changes-set-by-bristol-myers.html|url-status=live}}</ref>

In 1943, Bristol-Myers acquired Cheplin Biological Laboratories, a producer of [[acidophilus|acidophilus milk]] in [[East Syracuse, New York]],<ref>{{Cite book|last=Botti|first=Timothy J.|url=https://books.google.com/books?id=4UPo0V1qovwC&q=Squibb+world%27s+largest+penicillin+plant+for+army&pg=PA250|title=Envy of the World: A History of the U.S. Economy & Big Business|date=2006|publisher=Algora Publishing|isbn=978-0-87586-432-7|language=en|access-date=15 October 2020|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414045008/https://books.google.com/books?id=4UPo0V1qovwC&q=Squibb+world%27s+largest+penicillin+plant+for+army&pg=PA250|url-status=live}}</ref> and converted the plant to produce [[penicillin]] for the [[Allies of World War II|World War II Allied forces]].<ref>{{Cite web|date=13 September 2013|title=Bristol-Myers Squibb marks completion of East Syracuse plant's transformation|url=https://www.syracuse.com/news/2013/09/bristol-myers_squibb_marks_completion_of_east_syracuse_plants_transformation.html|access-date=9 July 2020|website=syracuse|language=en|archive-date=11 July 2020|archive-url=https://web.archive.org/web/20200711065151/https://www.syracuse.com/news/2013/09/bristol-myers_squibb_marks_completion_of_east_syracuse_plants_transformation.html|url-status=live}}</ref> After the war, the company renamed the plant [[Bristol Laboratories]] in 1945 and entered the civilian [[antibiotics]] market, where it faced competition from Squibb.<ref name="MarketingChannels" />

Penicillin production at the East Syracuse plant ended in 2005, when it became less expensive to produce overseas.<ref>{{Cite web|url=https://fortune.com/2014/06/02/fortune-500-bristol-myers/|title=Bristol-Myers Squibb: Big Pharma's small wonder|website=Fortune|language=en|access-date=10 December 2019|archive-date=10 December 2019|archive-url=https://web.archive.org/web/20191210192058/https://fortune.com/2014/06/02/fortune-500-bristol-myers/|url-status=live}}</ref><ref>{{Cite news|last=Harris|first=Gardiner|url=https://www.nytimes.com/2009/01/20/health/policy/20drug.html|title=Drug Making's Move Abroad Stirs Concerns|date=19 January 2009|work=The New York Times|access-date=26 March 2020|language=en-US|issn=0362-4331|archive-date=26 March 2020|archive-url=https://web.archive.org/web/20200326152244/https://www.nytimes.com/2009/01/20/health/policy/20drug.html|url-status=live}}</ref> As of 2010, the facility was used for the manufacturing process development and production of other [[biopharmaceutical|biologic medicines]] for clinical trials and commercial use.<ref>{{Cite web|url=https://www.syracuse.com/news/2010/06/at_bristol-myeres_squibb_plant.html|title=At Bristol-Myers Squibb plant in East Syracuse, old buildings will make way for new drugs|date=30 June 2010|website=syracuse|language=en|access-date=28 April 2020|archive-date=27 July 2020|archive-url=https://web.archive.org/web/20200727052549/https://www.syracuse.com/news/2010/06/at_bristol-myeres_squibb_plant.html|url-status=live}}</ref><ref>{{Cite web|url=https://www.pharmaceutical-technology.com/projects/bristolmyerseastsyra/|title=Bristol Myers Squibb East Syracuse Pharmaceutical Manufacturing Facility – Pharmaceutical Technology|website=www.pharmaceutical-technology.com|access-date=28 April 2020|archive-date=27 July 2020|archive-url=https://web.archive.org/web/20200727052503/https://www.pharmaceutical-technology.com/projects/bristolmyerseastsyra/|url-status=live}}</ref>

===Merger===
In 1989, Bristol-Myers and Squibb merged and became Bristol-Myers Squibb.<ref>{{Cite web|url=https://www.latimes.com/archives/la-xpm-1989-07-28-fi-295-story.html|title=Bristol-Myers, Squibb Agree to Merge : $12-Billion Stock Swap Would Form 2nd-Largest Drug Firm|date=28 July 1989|website=Los Angeles Times|language=en-US|access-date=26 March 2020|archive-date=26 March 2020|archive-url=https://web.archive.org/web/20200326151348/https://www.latimes.com/archives/la-xpm-1989-07-28-fi-295-story.html|url-status=live}}</ref>

In 1999, then-U.S. President Bill Clinton awarded Bristol-Myers Squibb the [[National Medal of Technology]], the nation's highest recognition for technological achievement, "for extending, and enhancing human life through innovative pharmaceutical research and development and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry."<ref>{{Cite web|url=https://www.nationalmedals.org/laureates/bristol-myers-squibb-company|title=NSTMF|website=NSTMF|access-date=26 March 2020|archive-date=26 March 2020|archive-url=https://web.archive.org/web/20200326151350/https://www.nationalmedals.org/laureates/bristol-myers-squibb-company|url-status=live}}</ref>

===2000 to 2010===
[[File:Bristol-Myers Squibb Logo.svg|right|thumb|Bristol-Myers Squibb logo from 1989 to 2020]]
[[Image:Bristol-Myers Squibb building at 100 Nassau Park Boulevard 2010.jpg|thumb|left|The company has a number of facilities in New Jersey; this one is on the border between West Windsor and Princeton.]]
In 2002, the company was involved in a lawsuit of illegally maintaining a monopoly on [[Taxol]], its cancer treatment, and it was again sued for the antitrust lawsuit five years later, which cost the company $125 million for settlement.<ref>{{cite news |url=https://money.cnn.com/2002/06/04/news/companies/bristol |title=Bristol hit with antitrust suit |date=4 June 2002 |access-date=10 July 2013 |work=CNN |archive-date=17 August 2020 |archive-url=https://web.archive.org/web/20200817125051/https://money.cnn.com/2002/06/04/news/companies/bristol/ |url-status=live }}</ref>

Also in 2002, Bristol-Myers Squibb was involved in an [[accounting scandal]] that resulted in a significant restatement of revenues from 1999 to 2001.<ref name=":8">{{Cite book|last=Chopra|first=Prem|url=https://books.google.com/books?id=Np3htQTKG10C&q=2002%2C+Bristol-Myers+Squibb+was+involved+in+an+accounting+scandal+that+resulted+in+a+significant+restatement+of+revenues+from+1999+to+2001&pg=PA327|title=Masters of the Game|date=2009|publisher=Brook of Life|isbn=978-0-9786321-3-7|language=en|access-date=15 October 2020|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414044839/https://books.google.com/books?id=Np3htQTKG10C&q=2002%2C+Bristol-Myers+Squibb+was+involved+in+an+accounting+scandal+that+resulted+in+a+significant+restatement+of+revenues+from+1999+to+2001&pg=PA327|url-status=live}}</ref> The restatement was the result of an improper booking of sales related to "[[channel stuffing]]" as the practice of offering excess inventory to customers to create higher sales numbers.<ref name=":8" /> The company has since settled with the [[United States Department of Justice]] and [[Securities and Exchange Commission]], agreeing to pay $150 million, while neither admitting nor denying guilt.<ref>{{cite press release |url= https://www.sec.gov/litigation/litreleases/lr18822.htm |title= Bristol-Myers Squibb Company : Lit. Rel. No. 18822 |publisher= US Securities and Exchange Commission |access-date= 9 May 2015 |date= 6 August 2004 |quote= Bristol-Myers inflated its results primarily by: (1) stuffing its distribution channels with excess inventory near the end of every quarter in amounts sufficient to meet sales and earnings targets set by officers ("channel-stuffing") |archive-date= 21 August 2017 |archive-url= https://web.archive.org/web/20170821063813/https://www.sec.gov/litigation/litreleases/lr18822.htm |url-status= live }}</ref>

On 24 October 2002, Bristol-Myers Squibb Co. restated earnings downward for parts of 2000 and 2001, while revising 2002 earnings upward because of its massive inventory backlog imbroglio that spurred two government investigations.<ref>{{cite web |url=http://www.highbeam.com/doc/1P1-68980061.html |archive-url=https://web.archive.org/web/20131105214250/http://www.highbeam.com/doc/1P1-68980061.html |url-status=dead |archive-date=5 November 2013 |title= Bristol-Myers to restate earnings as third quarter profits plunge}}</ref> On 15 March 2004, Bristol-Myers Squibb Co. adjusted upward its fourth-quarter and full-year 2003 results after reversing an earlier decision about how to deal with accounting errors made in prior years.<ref>{{cite web |url=http://www.highbeam.com/doc/1P1-92165333.html |archive-url=https://web.archive.org/web/20150924182701/http://www.highbeam.com/doc/1P1-92165333.html |url-status=dead |archive-date=24 September 2015 |title= Bristol-Myers restates results upward due to accounting errors}}</ref>

As part of a deferred prosecution agreement, the company was placed under the oversight of a monitor appointed by the U.S. attorney in New Jersey. In addition, the former head of the Pharma group, Richard Lane, and the ex-CFO, Fred Schiff, were indicted for federal securities violations.<ref>{{Cite news|last=Saul|first=Stephanie|date=15 June 2005|title=2 Former Bristol-Myers Executives Charged With Fraud|language=en-US|work=The New York Times|url=https://www.nytimes.com/2005/06/15/business/2-former-bristolmyers-executives-charged-with-fraud.html|access-date=9 July 2020|issn=0362-4331|archive-date=11 July 2020|archive-url=https://web.archive.org/web/20200711104240/https://www.nytimes.com/2005/06/15/business/2-former-bristolmyers-executives-charged-with-fraud.html|url-status=live}}</ref>

[[Image:Plavix 2007-04-19.jpg|thumb|right|upright=0.75]]
In July 2006, an investigation of the company was made public, and the [[FBI]] raided the company's corporate offices.<ref name=":9">{{Cite web|title=Former Bristol-Myers Squibb Senior Executive Pleads Guilty for Role in Dishonest Dealings with the Federal Government|url=https://www.fbi.gov/washingtondc/press-releases/2009/wfo040609.htm|access-date=9 July 2020|website=FBI|language=en-us|archive-date=19 October 2021|archive-url=https://web.archive.org/web/20211019181936/https://archives.fbi.gov/archives/washingtondc/press-releases/2009/wfo040609.htm|url-status=live}}</ref> The investigation centered on the distribution of [[Clopidogrel|Plavix]] and charges of [[collusion]].<ref name=":9" /><ref>[http://www.busrep.co.za/index.php?fSectionId=565&fArticleId=3367635 Business Report] {{webarchive |url=https://web.archive.org/web/20070817193955/http://www.busrep.co.za/index.php?fSectionId=565&fArticleId=3367635 |date=17 August 2007 }}, 31 July 2006. Retrieved 7 September 2006. Archived at</ref> On 12 September 2006, the monitor, former Federal Judge [[Frederick B. Lacey]], urged the company to remove then-CEO [[Peter R. Dolan|Peter Dolan]] over the Plavix dispute. Later that day, BMS announced that Dolan would indeed step down.<ref>[https://money.cnn.com/2006/09/12/news/companies/bristol/index.htm?postversion=2006091217 CNN.com] {{Webarchive|url=https://web.archive.org/web/20200915221735/https://money.cnn.com/2006/09/12/news/companies/bristol/index.htm?postversion=2006091217 |date=15 September 2020 }}, 12 September 2006. Retrieved 12 September 2006</ref>

The deferred prosecution agreement expired in June 2007 and the Department of Justice did not take any further legal action against the company for matters covered by the DPA. Under CEO Jim Cornelius, who was CEO following Dolan until May 2010, all executives involved in the "channel-stuffing" and generic competition scandals have since left the company.

In 2009, the company began a major restructuring focusing on the pharmaceutical business and biologic products, along with productivity initiatives and cost-cutting and streamlining business operations through a multiyear program of on-going layoffs. This was part of a business strategy launched in 2007 to transform the company from a large, diversified pharmaceutical company to a specialty biopharma company, which also included the closure of half of their manufacturing facilities.<ref name=":1">{{Cite news|url=https://www.qgdigitalpublishing.com/publication/?i=531504&p=&pn=#{%22issue_id%22:531504,%22page%22:20}|title=From Big to Specialty—The Operational Transformation of Bristol-Myers Squibb|last=Wright|first=Rob|date=October 2018|work=Life Science Leader|access-date=17 October 2018|publisher=VertMarkets|issue=10|location=Erie, Pennsylvania|volume=10}}</ref>{{Rp|19}} As another cost-cutting measure, Bristol-Myers Squibb also reduced health-care subsidies for retirees and planned to freeze their pension plan at the end of 2009.<ref>{{Cite web|url=https://www.plansponsor.com/bristol-meyers-squibb-announces-pension-risk-transfer/|title=Bristol-Myers Squibb Announces Pension Risk Transfer {{!}} PLANSPONSOR|website=www.plansponsor.com|access-date=28 April 2020|archive-date=27 July 2020|archive-url=https://web.archive.org/web/20200727035012/https://www.plansponsor.com/bristol-meyers-squibb-announces-pension-risk-transfer/|url-status=live}}</ref><ref>{{Cite web|url=https://www.ai-cio.com/news/bristol-myers-squibb-closes-us-retirement-plan/|title=Bristol-Myers Squibb Closes US Retirement Plan {{!}} Chief Investment Officer|website=www.ai-cio.com|date=6 December 2018 |access-date=28 April 2020|archive-date=27 July 2020|archive-url=https://web.archive.org/web/20200727041250/https://www.ai-cio.com/news/bristol-myers-squibb-closes-us-retirement-plan/|url-status=live}}</ref>

BMS is a ''Fortune'' 500 Company (#114 in 2010 list). ''Newsweek's ''2009 Green Ranking recognized Bristol-Myers Squibb as eighth among 500 of the largest United States corporations. Also, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.

[[Lamberto Andreotti]] was named [[Chief executive officer|CEO]] in 2010; he had previously served as "president and [[Chief operating officer|COO]] responsible for all pharmaceutical operations worldwide."<ref name=":0">{{Cite news|title = BMS CEO Andreotti to Retire; COO named as Successor|last = Staff|date = 15 February 2015|work = [[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]]|type = paper|page = 6|volume = 35|issue = 4}}</ref>

===2010 onward===
[[File:Bristol Myers Squibb, Moreton, Wirral - IMG 0369.JPG|thumb|left|Bristol-Myers Squibb facility in Wirral, England]]
In 2010, Lou Schmukler joined Bristol-Myers Squibb as the president of global product development and design.<ref name=":1" /><ref>{{Cite web|title=A Primer On Biopharma Manufacturing From Bristol-Myers Squibb's Lou Schmukler|url=https://www.lifescienceleader.com/doc/a-primer-on-biopharma-manufacturing-from-bristol-myers-squibb-s-lou-schmukler-0001|access-date=9 July 2020|website=www.lifescienceleader.com|archive-date=9 July 2020|archive-url=https://web.archive.org/web/20200709231446/https://www.lifescienceleader.com/doc/a-primer-on-biopharma-manufacturing-from-bristol-myers-squibb-s-lou-schmukler-0001|url-status=live}}</ref> Schmukler led the team that completed the company's strategic transformation to a specialty biopharmaceutical company that had begun in 2007.<ref name=":1" /> As of 2011, the company had a dozen manufacturing facilities and six product development sites.<ref name=":1" />

Citing major developments and a market capitalization of US$87 billion and stock appreciation of 61.4%, Bristol-Myers Squibb was ranked as the best drug company of 2013 by [[Forbes (magazine)|''Forbes'' magazine]].<ref>{{cite news |url=https://www.forbes.com/sites/matthewherper/2013/12/31/grading-pharma-in-2013-16-drug-companies-ranked/ |title=Grading Pharma in 2013 |work=Forbes |date=31 December 2013 |first=Matthew |last=Herper |access-date=25 August 2017 |archive-date=27 October 2017 |archive-url=https://web.archive.org/web/20171027035723/https://www.forbes.com/sites/matthewherper/2013/12/31/grading-pharma-in-2013-16-drug-companies-ranked/ |url-status=live }}</ref>

In December 2014, the company received FDA approval for the use of the [[PD-1]] inhibitor [[nivolumab]] (Opdivo) in treating patients whose skin cancer cannot be removed or have not responded to previous drug therapies.<ref>{{cite news|url=https://www.bloomberg.com/news/2014-12-22/bristol-myers-drug-wins-u-s-approval-to-treat-advanced-melanoma.html|title=Bristol-Myers Drug Wins U.S. Approval to Treat Advanced Melanoma|author=Anna Edney|publisher=Bloomberg|date=22 December 2014|access-date=5 March 2017|archive-date=31 December 2014|archive-url=https://web.archive.org/web/20141231234835/http://www.bloomberg.com/news/2014-12-22/bristol-myers-drug-wins-u-s-approval-to-treat-advanced-melanoma.html|url-status=live}}</ref> In February 2015, the company initiated a research partnership with Rigel Pharmaceuticals which could generate more than $339 million. In March, the company obtained an exclusive opportunity to both licence and commercialise [[PROSTVAC]], [[Bavarian Nordic]]'s phase III prostate-specific antigen targeting cancer immunotherapy. Bavarian Nordic would receive an upfront payment of $60 million and incremental payments up to $230 million, if the overall survival of test patients exceeds that seen in Phase II tests. Bavarian could also receive milestone payments of between $110 million and $495 million, dependent on regulatory authorization, and these payments have the potential to total up to $975 million.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/bavarian-nordic-could-tally-up-to-975m-in-prostate-cancer-deal-with-bms/81250993/|title=Bavarian Nordic Could Tally up to $975 Million in Prostate Cancer Deal with BMS – GEN News Highlights – GEN|work=GEN|date=4 March 2015|access-date=5 March 2015|archive-date=6 March 2015|archive-url=https://web.archive.org/web/20150306131553/http://genengnews.com/gen-news-highlights/bavarian-nordic-could-tally-up-to-975m-in-prostate-cancer-deal-with-bms/81250993/|url-status=live}}</ref>

In May 2015, Dr. Giovanni Caforio became CEO of the company;<ref name="ABC News">{{cite web|last1=Johnson|first1=Linda A.|title=New CEO Takes Over Evolving Drugmaker Bristol-Myers Squibb|url=https://abcnews.go.com/Business/wireStory/ceo-takes-drugmaker-bristol-myers-squibb-30816845|work=ABC News|access-date=6 May 2015|archive-date=7 May 2015|archive-url=https://web.archive.org/web/20150507193842/http://abcnews.go.com/Business/wireStory/ceo-takes-drugmaker-bristol-myers-squibb-30816845|url-status=live}}</ref> Caforio was formerly the company's [[Chief operating officer|COO]] and succeeded [[Lamberto Andreotti|Andreotti]] upon his retirement.<ref name=":0" /> Andreotti subsequently succeeded James Cornelius as [[Executive Chairman|executive chairman]] upon his retirement.<ref name=":0" />

In late February 2017, ''[[The Wall Street Journal]]'' and ''[[Fortune (magazine)|Fortune]]'', among others, reported that activist investor [[Carl Icahn]] had taken a stake in the company, signaling a potential future takeover<ref>{{cite web|url=http://fortune.com/2017/02/21/carl-icahn-bristol-myers-squibb/|title=Bristol-Myers Squibb Shares Just Spiked on Reports of a Carl Icahn Stake|website=Fortune|access-date=23 May 2017|archive-date=5 August 2017|archive-url=https://web.archive.org/web/20170805221623/http://fortune.com/2017/02/21/carl-icahn-bristol-myers-squibb/|url-status=live}}</ref><ref>{{cite web|url=https://www.wsj.com/articles/carl-icahn-takes-stake-in-bristol-myers-squibb-1487710151|title=Carl Icahn Takes Stake in Bristol-Myers Squibb|first1=David|last1=Benoit|first2=Jonathan D.|last2=Rockoff|date=22 February 2017|access-date=23 May 2017|work=The Wall Street Journal|archive-date=22 May 2017|archive-url=https://web.archive.org/web/20170522150438/https://www.wsj.com/articles/carl-icahn-takes-stake-in-bristol-myers-squibb-1487710151|url-status=live}}</ref> from the likes of [[Gilead Sciences]].<ref>{{cite web|url=http://www.fiercepharma.com/m-a/gilead-s-m-a-intentions-include-oncology-inflammation-ceo|title=Making (good) deals is hard to do, Gilead CEO says, but he's working on it – FiercePharma|website=fiercepharma.com|date=23 February 2017 |access-date=23 May 2017|archive-date=10 June 2017|archive-url=https://web.archive.org/web/20170610151034/http://www.fiercepharma.com/m-a/gilead-s-m-a-intentions-include-oncology-inflammation-ceo|url-status=live}}</ref>

In April 2018, the company reported net income of $1.5 billion, or 91 cents per share, for the first quarter of the year, thanks to the increased sales of their cancer drug Opdivo.<ref>{{Cite web|url=https://www.cnbc.com/2018/04/26/bristol-myers-squibb-q1-earnings-2018.html|title=Bristol-Myers' cancer drug Opdivo fuels growth, but revenue falls short|last=LaVito|first=Angelica|date=26 April 2018|publisher=CNBC|language=en|access-date=11 December 2019|archive-date=11 December 2019|archive-url=https://web.archive.org/web/20191211153534/https://www.cnbc.com/2018/04/26/bristol-myers-squibb-q1-earnings-2018.html|url-status=live}}</ref>

=== Corporate acquisitions and divestments as Bristol Myers Squibb ===
[[Image:Buspar.jpg|thumb|right|upright=0.75]]
In August 2009, during a major restructuring activity, BMS acquired the [[biotechnology]] firm [[Medarex]] as part of the company's "String of Pearls" strategy of alliances, partnerships, and acquisitions.<ref>https://finance.yahoo.com/news/BristolMyers-Squibb-to-bw-571310065.html?x=0&.v=1{{Dead link|date=February 2019 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>{{cite web |url=https://dealbook.nytimes.com/2009/07/23/bristol-myers-to-buy-medarex-for-24-billion/ |title=Bristol-Myers to Buy Medarex For $2.4 Billion |date=23 July 2009 |access-date=5 December 2020 |archive-date=14 April 2021 |archive-url=https://web.archive.org/web/20210414014334/https://dealbook.nytimes.com/2009/07/23/bristol-myers-to-buy-medarex-for-24-billion/ |url-status=live }}</ref> In November 2009, Bristol Myers Squibb announced that it was "splitting off" [[Mead Johnson|Mead Johnson Nutrition]] by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson.<ref name=":10">{{Cite web|last=Woelfel|first=Joseph|title=Bristol-Myers to Split Off Mead Johnson|url=https://www.thestreet.com/investing/stocks/bristol-myers-to-split-off-mead-johnson-10626920|access-date=9 July 2020|website=TheStreet|date=16 November 2009 |language=en-us|archive-date=10 July 2020|archive-url=https://web.archive.org/web/20200710015552/https://www.thestreet.com/investing/stocks/bristol-myers-to-split-off-mead-johnson-10626920|url-status=live}}</ref> According to Bristol Myers Squibb, this move was expected to further sharpen the company's focus on biopharmaceuticals.<ref name=":10" />

In October 2010, the company acquired [[ZymoGenetics]], securing an existing product, as well as pipeline assets in hepatitis C, cancer, and other therapeutic areas. {{cn|date=January 2025}}

Bristol Myers Squibb agreed to pay around $2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with [[Gilead Sciences|Gilead]]/[[Pharmasset]] to produce [[hepatitis C]] drugs. The settlement will be finished in 2 months for its Inhibitex's shareholders acceptance of 126% premium price of its price over the previous 20 trading days ended on 6 January.<ref>{{cite web|url=http://news.businessweek.com/article.asp?documentKey=1376-LXGOIL0UQVI901-5RJORL8I6BNJBGJ76B844E0GQP|title=Bristol Buys Inhibitex for $2.5 Billion to Compete in Hepatitis|date=8 January 2012}}{{dead link|date=April 2023|bot=medic}}{{cbignore|bot=medic}}</ref> On 29 June, BMS extended its portfolio of [[diabetes]] treatments when it agreed to buy [[Amylin Pharmaceuticals]] for around {{US$|5.3 billion}} in cash and pay {{US$|1.7 billion}} to [[Eli Lilly]] to cover Amylin's debt and its outstanding collaboration-related obligations.<ref name=":2">{{cite news|url=http://uk.reuters.com/article/uk-amylin-bristolmyerssquibb-idUKBRE85T01U20120630|title=Bristol-Myers to buy Amylin for about US$5.3 billion|last=Gershberg|first=Michele|date=30 June 2012|work=Reuters|access-date=5 July 2021|archive-date=9 August 2020|archive-url=https://web.archive.org/web/20200809103249/https://uk.reuters.com/article/uk-amylin-bristolmyerssquibb-idUKBRE85T01U20120630|url-status=dead}}</ref> [[Astra Zeneca|AstraZeneca]], which already collaborated on several diabetes treatments with BMS, agreed to pay US$3.4 billion in cash for the right to continue development of Amylin's products.<ref name=":2" /> Two years later, the company divested Amylin to AstraZeneca.<ref name=":1" />{{Rp|19}}

In April 2014, BMS announced its acquisition of iPierian for up to $725 million.<ref>{{cite news|date=|title=Bristol-Myers buy Inhibitex|work=Bristol-Myers Squibb|url=https://news.bms.com/news/details/2014/Bristol-Myers-Squibb-Acquires-iPierian-Inc/default.aspx|access-date=29 November 2021|archive-date=13 December 2015|archive-url=https://web.archive.org/web/20151213024325/http://news.bms.com/press-release/partnering-news/bristol-myers-squibb-acquires-ipierian-inc|url-status=live}}</ref>

In February 2015, the company acquired Flexus Biosciences for $1.25 billion. As part of this deal, BMS will gain full rights to Flexus' lead small molecule [[Indoleamine 2,3-dioxygenase#Inhibitors|IDO1-inhibitor]], F001287.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/bms-deals-add-to-its-immuno-oncology-portfolio/81250955/|title=GEN – News Highlights:BMS Deals Add to its Immuno-Oncology Portfolio|work=GEN|date=23 February 2015|access-date=24 February 2015|archive-date=24 February 2015|archive-url=https://web.archive.org/web/20150224015838/http://www.genengnews.com/gen-news-highlights/bms-deals-add-to-its-immuno-oncology-portfolio/81250955/|url-status=live}}</ref> In November, the company acquired the [[cardiovascular disease]] drug developer Cardioxyl for up to $2.075 billion. The deal strengthens the BMS' critical pipelines with the phase II candidate for [[acute decompensated heart failure]], [[CXL-1427]].<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/bms-to-buy-cardioxyl-for-up-to-2-075b/81251924/|title=BMS to Buy Cardioxyl for Up to $2.075B|work=GEN|date=2 November 2015|access-date=2 November 2015|archive-date=4 March 2016|archive-url=https://web.archive.org/web/20160304073238/http://www.genengnews.com/gen-news-highlights/bms-to-buy-cardioxyl-for-up-to-2-075b/81251924/|url-status=live}}</ref>

In March 2016, the company announced it would acquire Padlock Therapeutics for up to $600 million.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/bms-to-acquire-padlock-therapeutics-for-up-to-600m/81252509/|title=BMS to Acquire Padlock Therapeutics for Up to $600M|work=GEN|date=23 March 2016|access-date=23 March 2016|archive-date=6 September 2017|archive-url=https://web.archive.org/web/20170906140046/http://www.genengnews.com/gen-news-highlights/bms-to-acquire-padlock-therapeutics-for-up-to-600m/81252509|url-status=live}}</ref> In early July, the company announced it would acquire Cormorant Pharmaceuticals for $520 million, boosting BMS' oncology offering through Cormorants [[monoclonal antibody]] targeted against [[interleukin-8]].<ref name="genengaug2016">{{Cite journal|last=<!--journal staff-->|date=August 2016|title=BMS Snags Cormorant Pharmaceuticals for Up to $520M (online title: BMS Acquires Cormorant Pharmaceuticals for Up to $520M)|url=http://www.genengnews.com/gen-news-highlights/bms-acquires-cormorant-pharmaceuticals-for-up-to-520m/81252909/|department=News: Industry Watch (online: GEN News Highlights)|journal=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]]|volume=36|issue=14|page=10|access-date=5 July 2016|archive-date=10 July 2017|archive-url=https://web.archive.org/web/20170710110426/http://www.genengnews.com/gen-news-highlights/bms-acquires-cormorant-pharmaceuticals-for-up-to-520m/81252909|url-status=live}}</ref>

In August 2017 the company acquired [[IFM Therapeutics]] for $300 million upfront, with contingency payments of $1.01 billion due on certain milestones – allowing BMS to better compete against [[Merck & Co]]'s cancer rival treatment, [[Keytruda]].<ref>{{Cite news |date=3 August 2017 |title=Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline |url=http://uk.reuters.com/article/us-ifm-therapeutics-m-a-bristol-myers-idUKKBN1AJ2Z1 |url-status=dead |archive-url=https://web.archive.org/web/20170805221900/http://uk.reuters.com/article/us-ifm-therapeutics-m-a-bristol-myers-idUKKBN1AJ2Z1 |archive-date=5 August 2017 |access-date=5 August 2017 |work=Reuters}}</ref>

In early January 2019, the company announced it would acquire [[Celgene]] (NASDAQ:CELG) for $74 billion ($95 billion including debt<ref>{{Cite news|url=https://www.reuters.com/article/uk-celgene-m-a-bristol-myers-idUKKCN1OY1CA|title=Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal|newspaper=Reuters|date=4 January 2019|via=www.reuters.com|access-date=19 October 2021|archive-date=28 April 2021|archive-url=https://web.archive.org/web/20210428211323/https://www.reuters.com/article/uk-celgene-m-a-bristol-myers-idUKKCN1OY1CA|url-status=live}}</ref>), in a deal that would become the largest pharmaceutical-company acquisition ever.<ref name="bloomberg.com">{{cite web |url=https://www.bloomberg.com/news/articles/2019-01-03/bristol-myers-squibb-to-buy-celgene-in-74-billion-pharma-deal |title=Bristol Myers Squibb To Buy Celgene In $74 Billion Cancer-Drug Bet |first1=Rebecca |last1=Spalding |first2=Cynthia |last2=Koons |date=3 January 2019 |website=www.bloomberg.com |access-date=3 January 2019 |archive-date=3 January 2019 |archive-url=https://web.archive.org/web/20190103232910/https://www.bloomberg.com/news/articles/2019-01-03/bristol-myers-squibb-to-buy-celgene-in-74-billion-pharma-deal |url-status=live }}</ref> The Celgene acquisition aimed to be a refresher to the company's pipeline, helping to overcome from declining sales of [[Opdivo]] relative to competitor [[Keytruda]].<ref name=":3" /> Under the terms of the deal, Celgene shareholders would receive one BMS share as well as $50 in cash for each Celgene share held, valuing Celgene at $102.43 a share; representing a 54% premium to the previous days closing price.<ref name="bloomberg.com"/> Investor opposition to this acquisition, leading into a 12 April shareholder vote, appeared when BMS's second-largest investor, [[Wellington Management Company|Wellington Management]], voiced its opposition, followed by investor [[Starboard Value]].<ref name=":3">{{Cite news|url=https://www.reuters.com/article/us-celgene-m-a-bristol-myers-wellington/celgene-slumps-as-bristol-myers-shareholder-resists-merger-idUSKCN1QH1K7|title=Starboard joins opposition to Bristol-Myers' $74 billion Celgene deal|last1=Herbst-Bayliss|first1=Svea|date=28 February 2019|access-date=3 March 2019|work=Reuters|last2=Erman|first2=Michael|quote=Starboard reported on Thursday that it now owns 4.4 million shares, or 0.3 percent of Bristol's outstanding shares, while Wellington owns an 8 percent stake.|archive-date=28 February 2019|archive-url=https://web.archive.org/web/20190228174727/https://www.reuters.com/article/us-celgene-m-a-bristol-myers-wellington/celgene-slumps-as-bristol-myers-shareholder-resists-merger-idUSKCN1QH1K7|url-status=live}}</ref> In April 2019 BMS announced that 75% of its shareholders voted to approve the pending merger with Celgene. Transaction to close in the third quarter of 2019, subject to regulatory approvals.<ref>[https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-shareholders-approve-celgene-acquisition Bristol-Myers Squibb Shareholders Approve Celgene Acquisition] {{Webarchive|url=https://web.archive.org/web/20190510214239/https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-shareholders-approve-celgene-acquisition |date=10 May 2019 }}, PM BMS 12 April 2019, retrieved 13 May 2019</ref> Newly issued BMS shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol 'BMYRT'.<ref>{{Cite web|url=https://www.europeanpharmaceuticalreview.com/news/106288/bristol-myers-squibb-completes-acquisition-of-celgene/|title=Bristol-Myers Squibb completes acquisition of Celgene|date=22 November 2019|website=European Pharmaceutical Review|language=en|access-date=11 December 2019|archive-date=11 December 2019|archive-url=https://web.archive.org/web/20191211153540/https://www.europeanpharmaceuticalreview.com/news/106288/bristol-myers-squibb-completes-acquisition-of-celgene/|url-status=live}}</ref>

The strategic divestment of the company's consumer health business, UPSA, to [[Taisho Pharmaceutical|Taisho]] completed in 2019.<ref>{{Cite news|url=http://pharmabiz.com/ArticleDetails.aspx?aid=116689&sid=2|title=Bristol-Myers Squibb completes divestment of consumer health business, UPSA to Taisho Pharma|date=2 July 2019|work=Pharmabiz.com|access-date=4 July 2019|publisher=Saffron Media|location=India|type=Churnalism|archive-date=27 July 2020|archive-url=https://web.archive.org/web/20200727050244/http://pharmabiz.com/ArticleDetails.aspx?aid=116689&sid=2|url-status=live}}</ref> UPSA focused product delivery on France and the rest of Europe. As early as 2005, the company had divested individual consumer products,<ref name=":4" /><ref name=":5" /> and its US- and Canada-focused consumer products business.<ref name=":6" />

In August, the [[Amgen]] announced it would acquire the [[Otezla]] drug programme from [[Celgene]] for $13.4 billion, as part of Celgene and BMS's merger deal.<ref>{{Cite web|url=https://www.biospace.com/article/amgen-to-acquire-otezla-for-13-4-billion-in-cash-or-approximately-11-2-billion-net-of-anticipated-future-cash-tax-benefits/|title=Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits|website=BioSpace|access-date=19 October 2021|archive-date=19 October 2021|archive-url=https://web.archive.org/web/20211019181905/https://www.biospace.com/article/amgen-to-acquire-otezla-for-13-4-billion-in-cash-or-approximately-11-2-billion-net-of-anticipated-future-cash-tax-benefits/|url-status=live}}</ref><ref>{{Cite news|url=https://www.reuters.com/article/us-bristol-myers-divestiture-amgen-idUKKCN1VG102|title=Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion|newspaper=Reuters|date=26 August 2019|via=www.reuters.com|access-date=19 October 2021|archive-date=30 April 2021|archive-url=https://web.archive.org/web/20210430080227/https://www.reuters.com/article/us-bristol-myers-divestiture-amgen-idUKKCN1VG102|url-status=live}}</ref>

In February 2020, BMS and partner Biomotiv launched a new company called Anteros Pharmaceuticals, which focuses on creating inflammation and fibrosis medicines.<ref>{{Cite web|url=https://www.biopharmadive.com/news/bristol-myers-biomotive-launch-anteros-biotech/571650/|title=Bristol-Myers launches biotech targeting fibrosis, inflammation|website=BioPharma Dive|language=en-US|access-date=3 March 2020|archive-date=3 March 2020|archive-url=https://web.archive.org/web/20200303084944/https://www.biopharmadive.com/news/bristol-myers-biomotive-launch-anteros-biotech/571650/|url-status=live}}</ref> In August, the business announced it would acquire Forbius and its [[TGF-beta 1]] & [[TGF beta 3|TGF-beta 3]] inhibitors.<ref>{{Cite web|url=https://www.biospace.com/article/bristol-myers-squibb-enters-agreement-to-acquire-forbius-adding-lead-tgf-beta-asset-to-portfolio/|title=Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio|website=BioSpace|access-date=19 October 2021|archive-date=19 October 2021|archive-url=https://web.archive.org/web/20211019181905/https://www.biospace.com/article/bristol-myers-squibb-enters-agreement-to-acquire-forbius-adding-lead-tgf-beta-asset-to-portfolio/|url-status=live}}</ref> In October, BMS announced it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for [[Hypertrophic cardiomyopathy|obstructive hypertrophic cardiomyopathy]] (HCM), and the development of two key treatments: [[danicamtiv]] (MYK-491) and [[MYK-224]].<ref>{{cite web |url=https://www.biospace.com/article/bristol-myers-squibb-buys-myokardia-for-13-1-billion/ |title=BMS Strengthens Cardiovascular Business with $13.1 Billion MyoKardia Buyout |website=Biospace |date=5 October 2020 |access-date=18 November 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011064621/https://www.biospace.com/article/bristol-myers-squibb-buys-myokardia-for-13-1-billion/ |url-status=live }}</ref>

In June 2022, BMS announced it would acquire Turning Point Therapeutics Inc for $4.1 billion in cash ($76 per share, a 122.5% premium to its last closing price), helping to boost its complement of cancer drugs, specifically [[repotrectinib]].<ref>{{cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/ | title=Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal | newspaper=Reuters | date=3 June 2022 | last1=Mishra | first1=Manas | last2=Khandekar | first2=Amruta | access-date=4 June 2022 | archive-date=4 June 2022 | archive-url=https://web.archive.org/web/20220604205144/https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/ | url-status=live }}</ref> That same month, the company announced it would be investing $180m in French AI company [[Owkin]], to design potentially more precise and efficient clinical trials. The collaboration will initially focus on cardiovascular diseases, and has the potential to extend into projects in other therapeutic areas.<ref>{{Cite web |title=Bristol Myers pays $80M to AI firm Owkin as part of cardiovascular trial accord |url=https://www.fiercebiotech.com/cro/bristol-myers-pays-80m-ai-firm-owkin-part-cardiovascular-trial-accord |website=Fiercebiotech |date=9 June 2022 |access-date=22 March 2024 |archive-date=22 March 2024 |archive-url=https://web.archive.org/web/20240322122934/https://www.fiercebiotech.com/cro/bristol-myers-pays-80m-ai-firm-owkin-part-cardiovascular-trial-accord |url-status=live }}</ref>

In August 2023, Bristol Myers Squibb partnered with Cellares for the robotic production of CAR-T treatments of which it has two approved.<ref>{{Cite web |last=Dunleavy |first=Kevin |date=29 August 2023 |title=Bristol Myers Squibb partners with Cellares for robotic production of pipeline CAR-T drug |url=https://www.fiercepharma.com/manufacturing/bristol-myers-partners-cellares-robotic-manufacture-pipeline-car-t |access-date=27 September 2023 |website=Fierce Pharma |archive-date=27 September 2023 |archive-url=https://web.archive.org/web/20230927065229/https://www.fiercepharma.com/manufacturing/bristol-myers-partners-cellares-robotic-manufacture-pipeline-car-t |url-status=live }}</ref> In September 2023, BMS announced it would pay Zenas BioPharma $50m upfront for a strategic license and collaboration to develop and commercialise [[obexelimab]],<ref>{{Cite web |date=6 September 2023 |title=BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody |url=https://www.pmlive.com/pharma_news/bms_pays_zenas_$50m_upfront_for_regional_rights_to_autoimmune_disease_antibody_1498294 |access-date=15 September 2023 |website=PMLive |language=en |archive-date=25 September 2023 |archive-url=https://web.archive.org/web/20230925085346/https://www.pmlive.com/pharma_news/bms_pays_zenas_$50m_upfront_for_regional_rights_to_autoimmune_disease_antibody_1498294 |url-status=live }}</ref> a novel, bi-functional antibody for autoimmune diseases.

In October 2023, BMS agreed to acquire [[Mirati Therapeutics]], an American biotechnology company that develops targeted therapies for the treatment of cancer, in an all-cash deal worth $4.8&nbsp;billion, and an additional $1&nbsp;billion in milestone payment.<ref name=bms>{{Cite news |last=Condie |first=Stuart |date=8 October 2023 |title=Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion |url=https://www.wsj.com/health/pharma/bristol-myers-squibb-to-acquire-mirati-therapeutics-in-deal-worth-up-to-5-8-billion-7d83106 |work=The Wall Street Journal |access-date=8 October 2023 |archive-date=8 October 2023 |archive-url=https://web.archive.org/web/20231008231816/https://www.wsj.com/health/pharma/bristol-myers-squibb-to-acquire-mirati-therapeutics-in-deal-worth-up-to-5-8-billion-7d83106 |url-status=live }}</ref> The acquisition was completed in January 2024.<ref>{{Cite news |url=https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-mirati-acquisition/ |title=Bristol Myers Squibb concludes Mirati acquisition for $5.8bn |date=24 January 2024 |website=Pharmaceutical Technology |publisher=Verdict Media |access-date=28 January 2024 |archive-date=28 January 2024 |archive-url=https://web.archive.org/web/20240128014149/https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-mirati-acquisition/ |url-status=live }}</ref>

{{anchor|Karuna Therapeutics}}In December 2023, BMS signed an agreement for the acquisition of Karuna Therapeutics for an equity value totaling $14 billion.<ref name=":02">{{Cite web |last=Priyan |first=Vishnu |date=26 December 2023 |title=BMS agrees to acquire Karuna Therapeutics for $14bn |url=https://www.pharmaceutical-technology.com/news/bms-to-acquire-karuna/ |access-date=27 January 2024 |website=Pharmaceutical Technology |language=en-US |archive-date=27 January 2024 |archive-url=https://web.archive.org/web/20240127194949/https://www.pharmaceutical-technology.com/news/bms-to-acquire-karuna/ |url-status=live }}</ref> The acquisition included Karuna's lead asset, [[KarXT]], an investigational muscarinic antipsychotic combination of [[Xanomeline]] and [[Trospium chloride|Trospium]].<ref name=":03">{{Cite web |last=Priyan |first=Vishnu |date=26 December 2023 |title=BMS agrees to acquire Karuna Therapeutics for $14bn |url=https://www.pharmaceutical-technology.com/news/bms-to-acquire-karuna/ |access-date=27 January 2024 |website=Pharmaceutical Technology |language=en-US |archive-date=27 January 2024 |archive-url=https://web.archive.org/web/20240127194949/https://www.pharmaceutical-technology.com/news/bms-to-acquire-karuna/ |url-status=live }}</ref> In November 2023, the [[Food and Drug Administration|FDA]] accepted Karuna Therapeutics' [[New Drug Application|NDA]] for KarXT, for the treatment of schizophrenia in adults.<ref>{{Cite web |title=FDA accepts KarXT new drug application for treating schizophrenia |url=https://www.healio.com/news/psychiatry/20231129/fda-accepts-karxt-new-drug-application-for-treating-schizophrenia |access-date=27 January 2024 |website=www.healio.com |language=en |archive-date=27 January 2024 |archive-url=https://web.archive.org/web/20240127200703/https://www.healio.com/news/psychiatry/20231129/fda-accepts-karxt-new-drug-application-for-treating-schizophrenia |url-status=live }}</ref> The acquisition of Karuna Therapeutics was completed in March 2024.<ref>{{Cite web |date=18 March 2024 |title=Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio |url=https://finance.yahoo.com/news/bristol-myers-squibb-completes-acquisition-124400163.html |access-date=19 March 2024 |website=Yahoo Finance |language=en-US |archive-date=19 March 2024 |archive-url=https://web.archive.org/web/20240319082008/https://finance.yahoo.com/news/bristol-myers-squibb-completes-acquisition-124400163.html |url-status=live }}</ref>

The company entered into an agreement to purchase RayzeBio, for approximately $4.1 billion, in December 2023.<ref>{{cite news |last1=Lauerman |first1=John |title=Bristol Myers Adds to Buying Spree with Radiological Drugmaker |url=https://www.bloomberg.com/news/articles/2023-12-26/bristol-myers-adds-to-buying-spree-with-radiological-drugmaker?srnd=premium&sref=CIpmV6x8 |access-date=26 December 2023 |work=Bloomberg.com |date=26 December 2023 |language=en}}</ref>

On 26 September 2024, The Food and Drug Administration has given approval to one of Bristol Myers Squibb's most anticipated schizophrenia drugs named Cobenfy which is the first novel type of treatment for the devitalizing, chronic mental disorder in the last 70 years.<ref>{{Cite web |last=Constantino |first=Annika Kim |date=26 September 2024 |title=FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades |url=https://www.cnbc.com/2024/09/26/fda-approves-bristol-myers-squibbs-schizophrenia-drug.html |access-date=16 October 2024 |website=CNBC |language=en}}</ref>

===List of mergers and acquisitions===
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
{{Tree list}}
* '''Bristol-Myers Squibb''' <small>(Formed by the merger of Squibb Corporation (Est 1858) and Bristol-Myers (Est 1887))</small>
** Adnexus Therapeutics
** ConvaTec
** Kosan Biosciences
** [[Medarex]] <small>(Acq 2009)</small>
** [[ZymoGenetics]] <small>(Acq 2010)</small>
** Amira Pharmaceuticals
** Inhibitex Inc <small>(Acq 2012)</small>
** [[Amylin Pharmaceuticals]] <small>(Acq 2012 jointly with [[AstraZeneca]])</small>
** iPierian <small>(Acq 2014)</small>
** Flexus Biosciences <small>(Acq 2015)</small>
** Cardioxyl <small>(Acq 2015)</small>
** Padlock Therapeutics <small>(Acq 2016)</small>
** Cormorant Pharmaceuticals <small>(Acq 2016)</small>
** [[IFM Therapeutics]] <small>(Acq 2017)</small>
** [[Celgene]] <small>(Acq 2019)</small>
*** Signal Pharmaceuticals, Inc <small>(Acq 2000)</small>
*** Anthrogenesis <small>(Acq 2002)</small>
*** Pharmion Corporation <small>(Acq 2008)</small>
*** Gloucester Pharmaceuticals <small>(Acq 2009)</small>
*** Abraxis BioScience Inc <small>(Acq 2010)</small>
*** Avila Therapeutics, Inc <small>(Acq 2012)</small>
*** Quanticel <small>(Acq 2015)</small>
*** Receptos <small>(Acq 2015)</small>
*** EngMab AG <small>(Acq 2016)</small>
*** Delinia <small>(Acq 2017)</small>
*** Impact Biomedicines <small>(Acq 2018)</small>
*** [[Juno Therapeutics]] <small>(Acq 2018)</small>
**** AbVitro <small>(Acq 2016)</small>
**** RedoxTherapies <small>(Acq 2016)</small>
** Forbius <small>(Acq 2020)</small>
** MyoKardia <small>(Acq 2020)</small>
** Turning Point Therapeutics <small>(Acq 2022)</small>
** [[Mirati Therapeutics]] <small>(Acq 2024)</small>
** Karuna Therapeutics <small>(Acq 2024)</small>
** RayzeBio <small>(Acq 2024)</small>

{{Tree list/end}}

== Finances ==
For the fiscal year 2018,Bristol Myers Squibb reported earnings of US$1.007 billion, with an annual revenue of US$20.776 billion, an increase of 6.9% over the previous fiscal cycle. Bristol-Myers Squibb's shares traded at over $55 per share, and its market capitalization was valued at over US$81.6 billion in October 2018.<ref>{{Cite web|url=https://www.macrotrends.net/stocks/charts/BMY/bristol-myers-squibb/revenue|title=Bristol-Myers Squibb Revenue 2006–2018 {{!}} BMY|website=macrotrends.net|access-date=31 October 2018|archive-date=1 November 2018|archive-url=https://web.archive.org/web/20181101015725/https://www.macrotrends.net/stocks/charts/BMY/bristol-myers-squibb/revenue|url-status=live}}</ref> In 2018, 85% of the company's revenues came from just five products.<ref>{{Cite web|url=https://www.logistics.dhl/global-en/home/about-us/delivered-magazine/articles/2019/issue-3-2019/bristol-myers-squibb-diversity-scale-biopharma.html|title=Bristol-Myers Squibb: Diversity and scale in biopharma|date=June 2019|website=DHL|access-date=11 December 2019|archive-date=11 December 2019|archive-url=https://web.archive.org/web/20191211153538/https://www.logistics.dhl/global-en/home/about-us/delivered-magazine/articles/2019/issue-3-2019/bristol-myers-squibb-diversity-scale-biopharma.html|url-status=live}}</ref> In 2018, Bristol-Myers Squibb spent 36% of its total revenue on R&D expenses.<ref>{{Cite web|url=https://www.forbes.com/sites/greatspeculations/2019/11/28/what-percent-does-bristol-myers-squibb-spend-on-rd-30-40-or-50/|title=What Percent Does Bristol-Myers Squibb Spend On R&D, 30%, 40%, Or 50%?|date=28 November 2019|website=Forbes|language=en|access-date=11 December 2019|archive-date=11 December 2019|archive-url=https://web.archive.org/web/20191211153534/https://www.forbes.com/sites/greatspeculations/2019/11/28/what-percent-does-bristol-myers-squibb-spend-on-rd-30-40-or-50/|url-status=live}}</ref> Bristol-Myers Squibb ranked 145th on the [[Fortune 500]] list of the largest United States corporations by revenue in 2018.<ref>{{Cite web|url=http://fortune.com/fortune500/bristol-myers-squibb/|title=Bristol-Myers Squibb|website=Fortune|language=en-US|access-date=20 November 2018|archive-date=21 November 2018|archive-url=https://web.archive.org/web/20181121021955/http://fortune.com/fortune500/bristol-myers-squibb/|url-status=live}}</ref>
{| class="wikitable float-left" style="text-align: right;"
!Year
!Revenue<br />in bil. US$
!Net income<br />in bil. US$
!Total assets<br />in bil. US$
!Price per share<br />in US$
!Employees
|-
|2005
|18.60
|3.00
|28.14
|14.60
|
|-
|2006
|16.20
|1.59
|25.58
|15.24
|
|-
|2007
|15.62
|2.17
|25.93
|18.98
|
|-
|2008
|17.72
|5.25
|29.49
|14.95
|
|-
|2009
|18.81
| 10.60
|31.00
|15.90
|
|-
|2010
|19.48
| 3.09
|31.08
|19.76
|
|-
|2011
|21.24
|3.70
|32.97
|23.41
|
|-
|2012
|17.62
|1.96
|35.90
|28.04
|
|-
|2013
|16.39
|2.56
|38.60
|38.39
|28,000
|-
|2014
|15.88
|2.00
|33.75
|47.03
|25,000
|-
|2015
|16.56
| 1.57
|31.75
|59.63
|25,000
|-
|2016
|19.43
|4.45
|33.71
|59.73
|25,000
|-
|2017
|20.78
|1.00
|33.55
|55.88
|23,700
|-
|2018
|22.56
|4.92
|34.99
|51.98
|23,300
|-
|2019
|26.15
|3.44
|129.44
|52.23
|30,000
|-
|2020
|42.52
|−9.02
|118.48
|62.03
|30,250
|-
|2021
|46.39
|6.99
|109.31
|62.35
|32,200
|-
|2022
|46.16
|6.33
|96.82
|71.95
|34,300
|}

==Carbon footprint==
Bristol Myers Squibb reported Total [[carbon footprint|CO2e emissions]] (Direct + Indirect) for the twelve months ending 31 December 2020 at 278 Kt (-6 /-2.1% y-o-y).<ref name ="Bristol Myers Squibb Total CO2e emissions for 2020Q4">{{Cite web |title=Bristol Myers Squibb's Sustainability Report for 2020Q4 |archive-url=https://web.archive.org/web/20211010102301/https://www.bms.com/assets/bms/us/en-us/pdf/BMY-2020-ESG-Report.pdf |url=https://www.bms.com/assets/bms/us/en-us/pdf/BMY-2020-ESG-Report.pdf |archive-date=10 October 2021 }} [https://analytics.exerica.com/App/Name/Bristol%20Myers%20Squibb/Total%20CO2e%20Emissions%20-%20Location-Based%20Scope%201%20%2b%20Scope%202/2020Q4/12 Alt URL] {{Webarchive|url=https://web.archive.org/web/20211113115303/https://analytics.exerica.com/App/Name/Bristol%20Myers%20Squibb/Total%20CO2e%20Emissions%20-%20Location-Based%20Scope%201%20+%20Scope%202/2020Q4/12 |date=13 November 2021 }}</ref> The company aims to become net neutral carbon by 2040.<ref name ="Bristol Myers Squibb Total CO2e emissions for 2020Q4"/>

{| class="wikitable"
|+ Bristol Myers Squibb's annual Total CO2e Emissions - Location-Based Scope 1 + Scope 2 (in kilotonnes)<ref name ="Bristol Myers Squibb Total CO2e emissions for 2020Q4"/>
|-
! Dec 2016 !! Dec 2017 !! Dec 2018 !! Dec 2019 !! Dec 2020
|-
| 328 || 323|| 316 || 284 || 278
|}

==Pharmaceuticals==
[[File:HYDREA (ハイドレア).jpg|thumb|right|upright=0.75|Hydrea (hydroxycarbamide)]]
[[File:Atazanawir 300mg.jpg|thumb|right|upright=0.50|Reyataz (atazanavir)]]
The following is a list of key pharmaceutical products:<ref>{{cite web|title=Selected Products of Bristol-Myers Squibb|url=https://www.bms.com/patient-and-caregivers/our-medicines.html|publisher=© 2015 Bristol-Myers Squibb Company|access-date=30 May 2015|archive-date=4 May 2017|archive-url=https://web.archive.org/web/20170504023659/https://www.bms.com/patient-and-caregivers/our-medicines.html|url-status=live}}</ref>
{{div col start}}
''Cardiovascular diseases''
* Avalide ([[irbesartan]]/[[hydrochlorothiazide]]) – comarketed with [[Sanofi]]
* Avapro ([[irbesartan]]) – comarketed with [[Sanofi]]
* Camzyos ([[Mavacamten]])
* Coumadin ([[warfarin]])
* Eliquis ([[apixaban]]) – comarketed with [[Pfizer]]
* Plavix ([[clopidogrel]]) – comarketed with [[Sanofi]]
* Pravachol ([[pravastatin]])

''Diabetes mellitus''
* Bydureon ([[exenatide]] extended-release) – marketed by BMS only in some countries
* Byetta ([[exenatide]]) – marketed by BMS only in some countries, such as [[Russian Federation]]
* Farxiga/Forxiga ([[dapagliflozin]])
* Glucophage ([[metformin]]) – marketed by BMS only in USA
* Glucophage XR ([[metformin]] extended release) – marketed by BMS only in USA
* Glucovance ([[Glyburide/metformin]]) – marketed by BMS only in USA
* Kombiglyze XR/Komboglyze ([[saxagliptin]]/[[metformin]] extended release) – comarketed with [[AstraZeneca]]
* Onglyza ([[saxagliptin]]) – comarketed with [[AstraZeneca]]

''Infectious diseases, including [[HIV/AIDS|HIV infection]] and associated conditions''
* [[Atripla]] ([[efavirenz]]/[[emtricitabine]]/[[tenofovir disoproxil fumarate]]) – comarketed with [[Gilead Sciences]]
* Azactam ([[aztreonam]])
* Baraclude ([[entecavir]])
* Daklinza ([[daclatasvir]])
* Evotaz ([[atazanavir/cobicistat]])
* Megace ([[megestrol acetate]])
* Reyataz ([[atazanavir]])
* Sustiva/Stocrin ([[efavirenz]])
* Videx ([[didanosine]])
* Videx EC ([[didanosine]] delayed-release)
* Zerit ([[stavudine]])

''Inflammatory disorders''
* Kenalog-10 ([[triamcinolone acetonide]])
* Kenalog-40 (triamcinolone acetonide)

''Oncology''
* Abecma ([[idecabtagene vicleucel]])
* BiCNU ([[carmustine]])
* Breyanzi ([[lisocabtagene maraleucel]])
* CeeNU ([[lomustine]])
* Droxia/Hydrea ([[hydroxycarbamide]])
* Empliciti ([[Elotuzumab]])
* Erbitux ([[cetuximab]])
* Etopophos ([[etoposide]])
* Ixempra ([[ixabepilone]])
* Lysodren ([[mitotane]])
* Megace ([[megestrol acetate]])
* Opdivo ([[nivolumab]]) is a [[PD-1|programmed death receptor]] blocking antibody used for the treatment of unresectable or metastatic melanoma and metastatic squamous [[non-small-cell lung carcinoma]]. In contrast to traditional chemotherapies and targeted anti-cancer therapies, which exert their effects by direct cytotoxic or tumor growth inhibition, nivolumab acts by inducing the immune system to attack the tumor.<ref>{{cite journal |vauthors=Johnson DB, Peng C, Sosman JA |title=Nivolumab in melanoma: latest evidence and clinical potential |journal=Ther Adv Med Oncol |volume=7 |issue=2 |pages=97–106 |year=2015 |pmid=25755682 |pmc=4346215 |doi=10.1177/1758834014567469 }}</ref>
* Sprycel ([[dasatinib]])
* Taxol ([[paclitaxel]]). At one time, BMS held the solitary contract to harvest the bark of endangered [[Taxus brevifolia|yew]] trees on United States territory for the manufacture of [[chemotherapy]] drug [[paclitaxel]] (Taxol). Current paclitaxel production comes from renewable sources.{{citation needed|date=March 2015}} BMS also held the original paclitaxel license, but there are now multiple generic producers.<ref>{{cite web|url=https://www.drugs.com/availability/generic-taxol.html|title=Generic Taxol Availability|work=drugs.com|access-date=23 January 2018|archive-date=30 April 2016|archive-url=https://web.archive.org/web/20160430104706/http://www.drugs.com/availability/generic-taxol.html|url-status=live}}</ref>
* Vumon ([[teniposide]])
* Yervoy ([[ipilimumab]])

''Psychiatry''
* Abilify ([[aripiprazole]] comarketed with [[Otsuka Pharmaceutical]])
* Cobenfy ([[xanomeline/trospium chloride]])

''Rheumatic disorders''
* Orencia ([[abatacept]])

''Transplant rejection''
* Nulojix ([[belatacept]])
{{div col end}}

=== Out of production ===
* [[Sal Hepatica]]
* [[Ipana]]

===Divested brands===
(Former Bristol-Myers brands, now divested)
* [[Bufferin]]
* [[Excedrin]]<ref name=":4">{{cite news|url=https://money.cnn.com/2005/01/12/news/fortune500/bristol/index.htm|title=Excedrin brand for sale|date=12 January 2005|publisher=CNN Money|agency=Reuters|department=News > Fortune 500|access-date=3 August 2020|archive-date=16 April 2021|archive-url=https://web.archive.org/web/20210416115658/https://money.cnn.com/2005/01/12/news/fortune500/bristol/index.htm|url-status=live}}</ref>
* [[Mum (deodorant)|Ban Deodorant]]
* Vitalis (hair tonic)<ref name=":5">{{cite press release|url=http://www.prnewswire.com/news-releases/bristol-myers-squibb-to-divest-three-consumer-brands-76664287.html|title=Bristol-Myers Squibb to Divest Three Consumer Brands|date=21 September 1998|publisher=Bristol-Myers Squibb Company|via=PRNewswire|archive-date=4 March 2016|archive-url=https://web.archive.org/web/20160304115627/https://www.prnewswire.com/news-releases/bristol-myers-squibb-to-divest-three-consumer-brands-76664287.html}}</ref>{{Self-published inline|certain=yes|date=July 2019}}
* Ammens (medicated powder)
* Final Net (hair spray)
* Comtrex (cold relief capsules)
* [[Keri Lotion|Keri]] (lotion)<ref name=":6">{{cite press release|url=http://www.businesswire.com/news/home/20081211005659/en/Bristol-Myers-Squibb-Plans-Divest-U.S.-Canadian-Consumer|title=Bristol-Myers Squibb Plans To Divest U.S. And Canadian Consumer Medicines Business|date=12 January 2005|publisher=Bristol-Myers Squibb|via=BusinessWire|access-date=25 February 2016|archive-date=3 March 2016|archive-url=https://web.archive.org/web/20160303172455/http://www.businesswire.com/news/home/20081211005659/en/Bristol-Myers-Squibb-Plans-Divest-U.S.-Canadian-Consumer|url-status=live}}</ref>{{Self-published inline|certain=yes|date=July 2019}}

==Products under development==
[[Image:Beclabuvir.svg|thumb|right|upright=0.75|Beclabuvir]]
The following is a selective list of investigational products under development, as of 2023:<ref>{{cite web|title=Bristol-Myers Squibb: the Pipeline|url=https://www.bms.com/researchers-and-partners/in-the-pipeline.html|publisher=© 2015 Bristol-Myers Squibb Company|access-date=30 May 2015|archive-date=12 May 2015|archive-url=https://web.archive.org/web/20150512203055/https://www.bms.com/researchers-and-partners/in-the-pipeline.html|url-status=live}}</ref>
* [[Luspatercept]] - phase III: On 28 August 2023, BMS' drug Reblozyl has received FDA label expansion, making it a first-line treatment option for [[anemia]] in adults with low- to intermediate-risk [[myelodysplastic syndrome]]s (MDS) who may need regular blood transfusions. This decision, supported by data from the Phase III COMMANDS study, highlights Reblozyl's superiority over [[erythropoiesis-stimulating agent]]s (ESAs) in treating MDS-related anemia, potentially driving the drug's sales towards its $4 billion sales goal by 2030. The drug's efficacy in patients both with and without specific symptoms further widens its scope of application.<ref name="reblozy">{{Cite web|url=https://www.biospace.com/article/bms-gets-fda-label-expansion-for-potential-mega-blockbuster-reblozyl-/|title=BMS Gets FDA Label Expansion for Potential Mega Blockbuster Reblozyl|last=Goodwin|first=Kate|date=29 August 2023|website=www.biospace.com|access-date=30 August 2023|archive-date=31 August 2023|archive-url=https://web.archive.org/web/20230831055512/https://www.biospace.com/article/bms-gets-fda-label-expansion-for-potential-mega-blockbuster-reblozyl-/|url-status=live}}</ref><ref>{{cite web|url=https://packageinserts.bms.com/pi/pi_reblozyl.pdf|title=Highlights of prescribing information|website=packageinserts.bms.com|access-date=20 May 2024|archive-date=26 July 2024|archive-url=https://web.archive.org/web/20240726191231/https://packageinserts.bms.com/pi/pi_reblozyl.pdf|url-status=live}}</ref><ref>{{Cite journal|url=https://classic.clinicaltrials.gov/ct2/show/NCT02631070|title=A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)|website=classic.clinicaltrials.gov|date=19 November 2021 |access-date=30 August 2023|archive-date=30 August 2023|archive-url=https://web.archive.org/web/20230830125715/https://classic.clinicaltrials.gov/ct2/show/NCT02631070|url-status=live}}</ref>
* [[Beclabuvir]] (BMS-791325) – phase III
* [[BMS-906024]] – phase I
* [[BMS-955176]] – phase II
* [[Brivanib alaninate]] (BMS-582664) – development terminated
* [[Elotuzumab]] (BMS-901608) – phase III
* [[Fostemsavir]] (BMS-663068) – approved in the United States in July 2020
* [[Lirilumab]] (BMS-986015)
* [[Lulizumab pegol]] (BMS-931699) – phase II

== Public-private engagement ==
Bristol-Myers Squibb engages with the public and private sectors through the promotion of [[research and development]], academic funding, event sponsorship, [[philanthropy]], and [[political lobbying]].

=== Academia and education ===
* [[Institute for Advanced Study]] - Gift matching and direct donor.<ref>{{Cite web |last1=Simonyi |first1=Charles |last2=Dijkgraaf |first2=Robbert |date=2016 |title=Report for the Academic Year 2015-2016 |url=https://www.ias.edu/sites/default/files/documents/publications/2015-16Report.pdf |url-status=live |archive-url=https://web.archive.org/web/20220531231203/https://www.ias.edu/sites/default/files/documents/publications/2015-16Report.pdf |archive-date=31 May 2022 |access-date=2 August 2022 |website=[[Institute for Advanced Study]]}}</ref><ref>{{Cite web |last1=Simonyi |first1=Charles |last2=Dijkgraaf |first2=Robbert |date=2015 |title=Report for the Academic Year 2014-2015 |url=https://www.ias.edu/sites/default/files/documents/publications/annualreport1415_2.pdf |url-status=live |archive-url=https://web.archive.org/web/20220802184221/https://www.ias.edu/sites/default/files/documents/publications/annualreport1415_2.pdf |archive-date=2 August 2022 |access-date=2 August 2022 |website=[[Institute for Advanced Study]]}}</ref>
* Mentoring in IBD - Sponsor.<ref>{{Cite web |title=Sponsors |url=https://www.mentoringinibd.com/about-us/sponsors/ |url-status=live |archive-url=https://archive.today/20220419151936/https://www.mentoringinibd.com/about-us/sponsors/ |archive-date=19 April 2022 |access-date=19 June 2022 |website=Mentoring in IBD }}</ref>
* [[Northern Ontario School of Medicine]] (NOSM) - Donor.<ref>{{Cite web |title=Donor Wall |url=https://www.nosm.ca/advancement/giving/yourimpact/donor-wall/ |url-status=live |archive-url=https://web.archive.org/web/20220619175928/https://www.nosm.ca/advancement/giving/yourimpact/donor-wall/ |archive-date=19 June 2022 |access-date=19 June 2022 |website=[[Northern Ontario School of Medicine]]}}</ref>
* [[Population Health Research Institute]] (PHRI) at [[McMaster University Medical School]] - Partner.<ref>{{Cite web |title=Collaborations |url=https://www.phri.ca/collaborations/ |url-status=live |archive-url=https://archive.today/20220612052154/https://www.phri.ca/collaborations/ |archive-date=12 June 2022 |access-date=19 June 2022 |website=[[Population Health Research Institute]] |language=en-US }}</ref>
* [[University of Toronto]] - Donor.<ref>{{Cite web |title=Donor Listing |url=https://boundless.utoronto.ca/our-supporters/donor-listing/ |url-status=live |archive-url=https://archive.today/20210423095356/https://boundless.utoronto.ca/our-supporters/donor-listing/ |archive-date=23 April 2021 |access-date=20 June 2022 |website=[[University of Toronto]] |language=en }}</ref>
* [[University of Washington]] - Donor.<ref>{{Cite web |date=2020 |title=Honor Roll of Donors |url=https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf |url-status=live |archive-url=https://web.archive.org/web/20220610164520/https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf |archive-date=10 June 2022 |access-date=20 June 2022 |website=[[University of Washington]]; [[Amazon Web Services]]}}</ref>

=== Conferences and events ===
* Women in Medicine Summit - Sponsor.<ref>{{Cite web |title=Sponsors |url=https://www.womeninmedicinesummit.org/sponsors |url-status=live |archive-url=https://archive.today/20220507185453/https://www.womeninmedicinesummit.org/sponsors |archive-date=7 May 2022 |access-date=20 June 2022 |website=Women in Medicine |language=en-US }}</ref>
* World Neuroscience Innovation Forum - Sponsor.<ref>{{Cite web |title=Sponsors |url=https://neuroscienceinnovationforum.org/sponsors/ |url-status=usurped |archive-url=https://archive.today/20220615052144/https://neuroscienceinnovationforum.org/sponsors/ |archive-date=15 June 2022 |access-date=20 June 2022 |website=World Neuroscience Innovation Forum |language=en-US }}</ref>

=== Healthcare ===
* [[Centre for Addiction and Mental Health]] (CAMH) - Donor.<ref>{{Cite web |title=Thank you to our donors |url=https://www.camh.ca/-/media/files/camhf-2020-21-annual-report-donor-listing.pdf |url-status=live |archive-url=https://web.archive.org/web/20210629150832/https://www.camh.ca/-/media/files/camhf-2020-21-annual-report-donor-listing.pdf |archive-date=29 June 2021 |access-date=19 June 2022 |website=[[Centre for Addiction and Mental Health]]}}</ref>
* [[Princess Margaret Cancer Centre]] (PMCC) - Foundation donor and sponsor for the PMCC Conference.<ref>{{Cite web |title=2021 Annual Report |url=https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf |url-status=live |archive-url=https://web.archive.org/web/20211120191604/https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf |archive-date=20 November 2021 |access-date=20 June 2022 |website=[[Princess Margaret Cancer Centre|Princess Margaret Cancer Foundation]]}}</ref><ref>{{Cite web |title=The 8th Princess Margaret Hospital Conference |url=https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html |url-status=live |archive-url=https://web.archive.org/web/20220508062203/https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html?page=1 |archive-date=8 May 2022 |access-date=20 June 2022 |website=FDocuments India |language=en}}</ref>
* [[Scarborough Health Network]] (SHN) - Donor to the Scarborough Health Foundation.<ref>{{Cite web |title=Our Donors |url=https://www.shnfoundation.ca/our-donors/ |access-date=20 June 2022 |website=Scarborough Health Network Foundation |language=en-CA |archive-date=20 June 2022 |archive-url=https://web.archive.org/web/20220620072949/https://www.shnfoundation.ca/our-donors/ |url-status=live }}</ref>
* [[SickKids]] - Donor to the SickKids Foundation.<ref>{{Cite web |title=2020-21 SickKids Annual Report |url=https://web.sickkidsfoundation.com/annual-report-2020/ |url-status=live |archive-url=https://web.archive.org/web/20220620073404/https://web.sickkidsfoundation.com/annual-report-2020/ |archive-date=20 June 2022 |access-date=20 June 2022 |website=[[SickKids|SickKids Foundation]]}}</ref>
* [[Sinai Health System]] - Donor to the Sinai Health Foundation.<ref>{{Cite web |title=Donor List - Cumulative |url=https://www.sinaihealthannualreport.ca/donor-list-cumulative |url-status=live |archive-url=https://web.archive.org/web/20220516074624/https://www.sinaihealthannualreport.ca/donor-list-cumulative |archive-date=16 May 2022 |access-date=20 June 2022 |website=[[Sinai Health System]] |language=en}}</ref>
* [[Sunnybrook Health Sciences Centre]] - Donor.<ref>{{Cite web |title=Our donors - Your Impact - Sunnybrook Foundation |url=https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html |url-status=live |archive-url=https://web.archive.org/web/20220620153525/https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html |archive-date=20 June 2022 |access-date=20 June 2022 |website=[[Sunnybrook Health Sciences Centre]] |language=en}}</ref>

=== Media ===
* [[National Geographic Society]] - Donor.<ref>{{Cite web |title=2016 Annual Report Donor List |url=https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf |url-status=live |archive-url=https://web.archive.org/web/20220510054615/https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf |archive-date=10 May 2022 |access-date=19 June 2022 |website=[[National Geographic Society]]}}</ref>
* [[National Press Foundation]] - Funder.<ref>{{Cite web |date=26 September 2010 |title=Our Funders |url=http://nationalpress.org/about/our-funders/ |url-status=dead |archive-url=https://web.archive.org/web/20100926162431/http://nationalpress.org/about/our-funders/ |archive-date=26 September 2010 |access-date=19 June 2022 |website=[[National Press Foundation]]; [[Wayback Machine]]}}</ref>

=== Medical societies ===
* [[American Society of Hematology]] (ASH) - Corporate supporter.<ref>{{Cite web |title=Corporate Support |url=https://www.hematology.org:443/about/corporate-support |url-status=live |archive-url=https://archive.today/20220610180740/https://www.hematology.org/about/corporate-support |archive-date=10 June 2022 |access-date=18 June 2022 |website=[[American Society of Hematology]] |language=en }}</ref>
* Arthritis Society - National corporate partner.<ref>{{Cite web |title=Partners |url=https://arthritis.ca/about-us/partners |url-status=live |archive-url=https://archive.today/20220514211808/https://arthritis.ca/about-us/partners |archive-date=14 May 2022 |access-date=18 June 2022 |website=Arthritis Society }}</ref>
* Canadian Society of Internal Medicine - Sponsor.<ref>{{Cite web |title=Sponsors |url=https://csim.ca/conferences/virtual-annual-meeting-2021/sponsors/ |url-status=live |archive-url=https://archive.today/20220515012338/https://csim.ca/conferences/virtual-annual-meeting-2021/sponsors/ |archive-date=15 May 2022 |access-date=19 June 2022 |website=Canadian Society of Internal Medicine |language=en-US }}</ref>
* [[European Society of Cardiology]] - Sponsor.<ref>{{Cite web |title=Why sponsor the EURObservational Registry Programme |url=https://www.escardio.org/Research/Registries-&-surveys/Sponsorship,%20https://www.escardio.org/Research/Registries-&-surveys/Sponsorship |url-status=live |archive-url=https://archive.today/20220615200912/https://www.escardio.org/Research/Registries-&-surveys/Sponsorship |archive-date=15 June 2022 |access-date=19 June 2022 |website=[[European Society of Cardiology]] }}</ref>
* Spanish Cardiac Society - Partner.<ref>{{Cite web |title=Sociedad Española de Cardiología: profesionales sanitarios y cardiólogos |url=https://secardiologia.es/ |url-status=live |archive-url=https://web.archive.org/web/20220613161701/https://secardiologia.es/ |archive-date=13 June 2022 |access-date=20 June 2022 |website=[[Socieded Española de Cardiología]] |language=es}}</ref>

=== Political lobbying ===
* [[BIOTECanada]] - Member company.<ref>{{Cite web |date=23 December 2021 |title=Member Listings |url=https://www.biotech.ca/about/member-listings/ |url-status=live |archive-url=https://web.archive.org/web/20220502074149/https://www.biotech.ca/about/member-listings/ |archive-date=2 May 2022 |access-date=18 June 2022 |website=[[BIOTECanada]] |language=en-US}}</ref> BIOTECanada lobbies the Canadian government for policies favorable to the [[Pharmaceutical industry in Canada|pharmaceutical industry]].<ref>{{Cite web |last=Wilson |first=Barry |date=5 October 2000 |title=Biotech lobby group at heart of ethics complaint |url=https://www.producer.com/news/biotech-lobby-group-at-heart-of-ethics-complaint/ |url-status=live |archive-url=https://archive.today/20220618172657/https://www.producer.com/news/biotech-lobby-group-at-heart-of-ethics-complaint/ |archive-date=18 June 2022 |access-date=18 June 2022 |website=[[The Western Producer]] |language=en }}</ref>
* [[Innovative Medicines Canada]] - Member.<ref>{{Cite web |title=Member Companies |url=http://innovativemedicines.ca/about/member-companies/ |url-status=live |archive-url=https://archive.today/20211103040804/http://innovativemedicines.ca/about/member-companies/ |archive-date=3 November 2021 |access-date=19 June 2022 |website=Innovative Medicines Canada |language=en }}</ref>
* [[International Federation of Pharmaceutical Manufacturers & Associations]] (IFPMA) - Member.<ref>{{Cite web |title=Companies |url=https://www.ifpma.org/who-we-are/our-membership/full-members/companies/ |url-status=live |archive-url=https://web.archive.org/web/20220619085601/https://www.ifpma.org/who-we-are/our-membership/full-members/companies/ |archive-date=19 June 2022 |access-date=19 June 2022 |website=[[International Federation of Pharmaceutical Manufacturers and Associations]] |language=en-GB}}</ref>
* [[National Health Council]] - Member.<ref>{{Cite web |title=Our Members |url=https://nationalhealthcouncil.org/members/ |access-date=19 June 2022 |website=National Health Council |language=en-US |archive-date=6 April 2022 |archive-url=https://web.archive.org/web/20220406081753/https://nationalhealthcouncil.org/members/?m_cat=74&m_key= |url-status=live }}</ref>
* National Pharmaceutical Council - Member.<ref>{{Cite web |title=Members |url=https://www.npcnow.org/about/members |url-status=live |archive-url=https://web.archive.org/web/20211102074208/https://www.npcnow.org/about/members |archive-date=2 November 2021 |access-date=19 June 2022 |website=[[National Pharmaceutical Council]] |language=en}}</ref>
* Personalized Medicine Coalition - Member.<ref>{{Cite web |title=Current Members |url=https://personalizedmedicinecoalition.org/Members/Current_Members |url-status=live |archive-url=https://web.archive.org/web/20210815032705/https://personalizedmedicinecoalition.org/Members/Current_Members |archive-date=15 August 2021 |access-date=19 June 2022 |website=[[Personalized Medicine Coalition]] |language=en}}</ref>
* [[Pharmaceutical Advertising Advisory Board]] - Client.<ref>{{Cite web |last= |first= |title=PAAB : About |url=https://www.paab.ca/about.htm |url-status=live |archive-url=https://archive.today/20180924200521/https://www.paab.ca/about.htm |archive-date=24 September 2018 |access-date=19 June 2022 |website=Pharmaceutical Advertising Advisory Board / Conseil Consultatif de Publicité Pharmaceutique |language=en }}</ref>
* [[Pharmaceutical Research and Manufacturers of America]] - Member.<ref>{{Cite web |title=About |url=https://phrma.org/About |url-status=live |archive-url=https://web.archive.org/web/20220615053053/https://www.phrma.org/About |archive-date=15 June 2022 |access-date=19 June 2022 |website=[[Pharmaceutical Research and Manufacturers of America]] |language=en}}</ref>
* Research!America - Member.<ref>{{Cite web |date= |title=Member Organizations |url=https://www.researchamerica.org/about-us/member-organizations |url-status=live |archive-url=https://archive.today/20220406092643/https://www.researchamerica.org/about-us/member-organizations |archive-date=6 April 2022 |access-date=20 June 2022 |website=Research!America |language=en }}</ref>

=== Professional associations ===
* [[Canadian Association of Emergency Physicians]] (CAEP) - Corporate partner.<ref>{{Cite web |date=2019 |title=Annual Report 2018-2019 |url=https://caep.ca/wp-content/uploads/2019/06/Annual-Report2019-V2.pdf |url-status=live |archive-url=https://web.archive.org/web/20220420013556/https://caep.ca/wp-content/uploads/2019/06/Annual-Report2019-V2.pdf |archive-date=20 April 2022 |access-date=18 June 2022 |website=[[Canadian Association of Emergency Physicians]]}}</ref>
* [[Canadian Rheumatology Association]] (CRA) - Corporate sponsor.<ref>{{Cite web |date=2021 |title=Corporate Sponsors |url=https://rheum.ca/about-us/corporate-sponsors/ |url-status=live |archive-url=https://archive.today/20220301090853/https://rheum.ca/about-us/corporate-sponsors/ |archive-date=1 March 2022 |access-date=18 June 2022 |website=[[Canadian Rheumatology Association]] |language=en-US }}</ref><ref>{{Cite web |last1=Ahluwalia |first1=Vandana |last2=Zbib |first2=Ahmad |date=2019 |title=2018-2019 Annual Report |url=https://rheum.ca/wp-content/uploads/2019/06/cra-scr-annual-report-2019-EN-WEB.pdf |url-status=live |archive-url=https://web.archive.org/web/20220301085355/https://rheum.ca/wp-content/uploads/2019/06/cra-scr-annual-report-2019-EN-WEB.pdf |archive-date=1 March 2022 |access-date=18 June 2022 |website=[[Canadian Rheumatology Association]]}}</ref><ref>{{Cite web |date=2020 |title=2019-2020 Annual Report |url=https://rheum.ca/wp-content/uploads/2020/09/ARD20_CR02_P01_cra_scr_annual_report_2020_v8b.pdf |url-status=live |archive-url=https://web.archive.org/web/20220301060726/https://rheum.ca/wp-content/uploads/2020/09/ARD20_CR02_P01_cra_scr_annual_report_2020_v8b.pdf |archive-date=1 March 2022 |access-date=18 June 2022 |website=[[Canadian Rheumatology Association]]}}</ref>
* CARE Faculty - Sponsor. CARE is a Canadian coalition of medical specialists based in Oakville, Ontario. BMS was a sponsor for their 2021 Winter Hematology Update event.<ref>{{Cite web |title=Dr. Coleman Rotstein - COVID-19 Vaccines in Oncology Patients |url=https://careeducation.ca/dr-coleman-rotstein-covid-19-vaccines-in-oncology-patients/ |url-status=live |archive-url=https://archive.today/20220419144918/https://careeducation.ca/dr-coleman-rotstein-covid-19-vaccines-in-oncology-patients/ |archive-date=19 April 2022 |access-date=19 June 2022 |website=CARE™ Education |language=en-US }}</ref>
* Colorectal Cancer Canada (CRC) - Sponsor.<ref>{{Cite web |title=Our Partnerships |url=https://www.colorectalcancercanada.com/what-we-do/our-partnerships/ |access-date=19 June 2022 |website=Colorectal Cancer Canada |language=en |archive-date=16 May 2022 |archive-url=https://web.archive.org/web/20220516082302/https://www.colorectalcancercanada.com/what-we-do/our-partnerships/ |url-status=dead }}</ref>
* Health Products Stewardship Association - Member.<ref>{{Cite web |last= |first= |title=Members |url=https://healthsteward.ca/members/hpsa-members/ |url-status=live |archive-url=https://archive.today/20220427100339/https://healthsteward.ca/members/hpsa-members/ |archive-date=27 April 2022 |access-date=19 June 2022 |website=Health Products Stewardship Association |language=en-US }}</ref>

=== Research and development ===
* Lung Health Foundation - Partner.<ref>{{Cite web |title=Our Partners |url=https://lunghealth.ca/our-partners/ |access-date=19 June 2022 |website=Lung Health Foundation |language=en-US |archive-date=9 June 2022 |archive-url=https://archive.today/20220609004346/https://lunghealth.ca/our-partners/ |url-status=live }}</ref>
* [[Multiple Sclerosis International Federation]] - Partner.<ref>{{Cite web |title=How we work with the healthcare industry |url=https://www.msif.org/about-us/how-we-are-funded/work-healthcare-industry/ |access-date=19 June 2022 |website=MS International Federation |language=en |archive-date=19 June 2022 |archive-url=https://web.archive.org/web/20220619232106/https://www.msif.org/about-us/how-we-are-funded/work-healthcare-industry/ |url-status=live }}</ref>
* Pinnacle Research Group - Sponsor.<ref>{{Cite web |title=Sponsors and CRO's |url=http://www.pinnacletrials.com/sponsors/ |url-status=live |archive-url=https://archive.today/20220612095635/http://www.pinnacletrials.com/sponsors/ |archive-date=12 June 2022 |access-date=19 June 2022 |website=[[Pinnacle Research Group]] |language=en-US }}</ref>
* Radcliffe Cardiology - Industry partner.<ref>{{Cite web |title=A-Z |url=https://www.radcliffecardiology.com/products-services/a-z |url-status=live |archive-url=https://web.archive.org/web/20220612062914/https://www.radcliffecardiology.com/products-services/a-z |archive-date=12 June 2022 |access-date=20 June 2022 |website=Radcliffe Cardiology}}</ref>

==Scandals==
{{Criticism section|date=March 2023}}
Bristol-Myers Squibb, [[Johns Hopkins University]] and the [[Rockefeller Foundation]] are currently the subject of a $1 billion lawsuit from [[Guatemala]] for "roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with [[syphilis]]".<ref>{{cite news|title=Johns Hopkins, Bristol-Myers must face $1 billion syphilis infections suit|website=[[Reuters]]|date=4 January 2019 |url=https://www.reuters.com/article/us-maryland-lawsuit-infections-idUSKCN1OY1N3|access-date=27 March 2020|archive-date=18 January 2021|archive-url=https://web.archive.org/web/20210118011339/https://www.reuters.com/article/us-maryland-lawsuit-infections-idUSKCN1OY1N3|url-status=live}}</ref> A previous suit against the [[United States]] government was dismissed in 2011 for the [[Guatemala syphilis experiments]] when a judge determined that the U.S. government could not be held liable for actions committed outside of the U.S.<ref>{{cite news|url=https://psmag.com/news/the-guatemala-experiments|title=The Guatemala Experiments|last=Mariani|first=Mike|date=28 May 2015|newspaper=Pacific Standard|access-date=7 January 2015|publisher=The Miller-McCune Center for Research, Media and Public Policy|archive-date=10 February 2020|archive-url=https://web.archive.org/web/20200210200654/https://psmag.com/news/the-guatemala-experiments|url-status=live}}</ref>

==See also==
* [[List of biotech and pharmaceutical companies in the New York metropolitan area]]

== References ==
{{reflist|30em}}

==External links==
{{Commons category}}
* {{Official|https://www.bms.com}}
{{Finance links
| name = Bristol-Myers Squibb Company
| symbol = BMY
| sec_cik = 14272
| yahoo = BMY
| google = BMY:NYSE
}}

{{Pharmaceutical companies of the United States}}

{{Authority control}}

[[Category:Bristol Myers Squibb| ]]
[[Category:1920s initial public offerings]]
[[Category:American companies established in 1887]]
[[Category:Biotechnology companies of the United States]]
[[Category:Companies listed on the New York Stock Exchange]]
[[Category:Pharmaceutical companies established in 1887]]
[[Category:Pharmaceutical companies based in New Jersey]]
[[Category:1887 establishments in New York (state)]]
[[Category:National Medal of Technology recipients]]
[[Category:Life sciences industry]]